var title_f8_58_9120="Labial eruption";
var content_f8_58_9120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Labial eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 157px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. A reduction in the width of keratinized gingiva resulting from labial eruption of the left central incisor. B. After orthodontic alignment of the labially positioned left incisor, a gingival defect was observed. Localized recession occurred as the result of plaque accumulation in an area that was difficult to clean and had inadequate attached gingiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Griffen AL. Periodontal problems in children and adolescents. In: Pediatric Dentistry, Infancy Through Adolescence, 3rd ed, Pinkham, Casamassimo, Fields, McTigue, Nowak (Eds), W.B. Saunders, 1999. p.376. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9120=[""].join("\n");
var outline_f8_58_9120=null;
var title_f8_58_9121="Xipamide: International drug information";
var content_f8_58_9121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Xipamide: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aquafor (IT);",
"     </li>",
"     <li>",
"      Aquaphor (DE, IT);",
"     </li>",
"     <li>",
"      Aquaphoril (AT);",
"     </li>",
"     <li>",
"      Chronexan (FR);",
"     </li>",
"     <li>",
"      Demiax (ES);",
"     </li>",
"     <li>",
"      Diurex (ES);",
"     </li>",
"     <li>",
"      Diurexan (BE, GB, IE, LU, PT);",
"     </li>",
"     <li>",
"      Lumitens (FR);",
"     </li>",
"     <li>",
"      Xipamid (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Thiazide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of edema; hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Edema: Initial: 40 mg in the morning; may increase to 80 mg in resistant cases; maintenance dose: 20 mg in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypertension: 20 mg in the morning",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10441 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7C479FB97E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9121=[""].join("\n");
var outline_f8_58_9121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304163\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980438\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980441\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980437\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821163\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980440\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_58_9122="Repair of common bile duct injury over a T tube";
var content_f8_58_9122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Repair of common bile duct injury over a T-tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A T-tube may be placed after laparoscopic or open common bile duct exploration. The largest caliber T-tube the duct will accomodate should be selected. Tapering the ends of the t-tube&nbsp;catheter with a scissors facilitates intraductal placement. In addition, opening the intraductal portion of the T-tube along its length opposite the junction of the intraabdominal&nbsp;portion will&nbsp;allow the catheter to collapse when it is removed. The catheter should be secured in the bile duct using fine monofilament sutures, taking care not to suture into&nbsp;the catheter. A completion T-tube cholangiogram is performed prior to abdominal closure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9122=[""].join("\n");
var outline_f8_58_9122=null;
var title_f8_58_9123="EB nevi 3";
var content_f8_58_9123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A typical flat, stippled epidermolysis bullosa naevus in a 13-year-old patient with dystrophic epidermolysis bullosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9123=[""].join("\n");
var outline_f8_58_9123=null;
var title_f8_58_9124="Intermediate case 7 with answer";
var content_f8_58_9124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Atrial fibrillation with left bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 127px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial fibrillation, as evidenced by the rapid fibrillatory (f) waves and the irregularly irregular R-R interval, with left bundle branch block, as evidenced by the prolonged QRS complex (0.16 sec) which has a QS pattern in V1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9124=[""].join("\n");
var outline_f8_58_9124=null;
var title_f8_58_9125="Frykman I radius fracture AP view";
var content_f8_58_9125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61535%7EEM%2F74330%7EEM%2F78794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61535%7EEM%2F74330%7EEM%2F78794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman I radius fracture AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This x-ray, taken of a 23-year-old snowboarder after she fell back onto her outstretched left hand, shows a Frykman I distal radius fracture. The x-ray shows several abnormalities including a significant loss of radial height, decreased radial inclination, and positive ulnar variance. Also, several fracture lines are present (black arrows), indicating comminution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman I radius fracture lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On the lateral x-ray of the same fracture, the dorsal angulation of the distal fragment is apparent. Such fractures are often referred to by the eponym Colles'. Note this is not a true lateral: the images of the radius and ulna are not superimposed, and the pisiform (black arrow) is seen dorsal to the distal pole of the scaphoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman I radius fracture oblique view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The oblique view of the same fracture highlights the loss of radial height.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9125=[""].join("\n");
var outline_f8_58_9125=null;
var title_f8_58_9126="Nerves of the female perineum";
var content_f8_58_9126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Nerves of the female perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9126=[""].join("\n");
var outline_f8_58_9126=null;
var title_f8_58_9127="LV Doppler flow patterns";
var content_f8_58_9127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65233%7ECARD%2F59321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65233%7ECARD%2F59321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal left ventricular Doppler flow patterns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the Doppler beam directed from apex to base, a variety of Doppler flow velocity patterns within the left ventricle (LV) can be obtained. The position of the sample volume for recording each of these patterns is shown in the diagram of an apical \"five-chamber\" view. Pattern #1 is flow within the left ventricular (or mitral valve) inflow tract (LVIT) as recorded from the tip of the mitral valve on its left ventricular side. The M-shaped inflow pattern is nearly identical to the M-mode image of mitral leaflet motion. The initial velocity peak represents the highest velocity achieved during the passive or rapid filling (RF) phase; the lower peak velocity represents the atrial (A) inflow phase. Although there is similarity in the appearance between the mitral M-mode motion and Doppler flow signals, there is very little predictive value of one for the other. Pattern #3 is flow within the left ventricular outflow tract (LVOT), representing systolic flow leaving the LV; this systolic signal demonstrates flow away from the transducer or away from the apex. Pattern #2 (LVIT/LVOT) is a hybrid mixture of #1 and #3 and gives inaccurate information about either. It is important to sample the Doppler flow signal axial to its flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal Doppler echocardiographic transmitral diastolic inflow pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The recording of the transmitral diastolic inflow (panel B) is obtained by placing the Doppler sample volume between the tips of the open mitral valve leaflets, as shown in panel A. The most commonly measured values are given in tabular format (panel C) and the site of the pulsed wave Doppler sample volume is shown un the upper left panel.",
"    <div class=\"footnotes\">",
"     m/s: meters per second; VTI: velocity time integral; ms: milliseconds.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9127=[""].join("\n");
var outline_f8_58_9127=null;
var title_f8_58_9128="Inter-facility maternal transport";
var content_f8_58_9128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inter-facility maternal transport",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9128/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9128/contributors\">",
"     Stephanie R Martin, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9128/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9128/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/58/9128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21515537\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfer of the complicated pregnant patient to a facility with appropriate medical, surgical, obstetric, or pediatric resources can reduce maternal, fetal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neonatal morbidity and mortality. The most common reason for maternal transfer is availability of neonatal tertiary care; transferring the undelivered woman is preferable to neonatal transport and should be a primary goal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/1\">",
"     1",
"    </a>",
"    ]. Maternal transfers are also performed for maternal medical or surgical conditions to accommodate family request, to comply with insurance contract requirements, or when a pregnant woman seeks emergency care at a facility without obstetrical services.",
"   </p>",
"   <p>",
"    Although most hospitals are not expected to provide obstetric units or tertiary neonatal care, they should be prepared to stabilize obstetric patients who present for emergency care or who have complicated pregnancies. This preparation includes having a prearranged transfer agreement that identifies the preferred receiving obstetric care facility, mode of transport, and method of clinician-to-clinician contact.",
"   </p>",
"   <p>",
"    Transport may occur by ground (ambulance), helicopter, or fixed wing plane. An obvious concern is the possibility of delivery during transport, when minimal resources are available.",
"   </p>",
"   <p>",
"    A general guide for inter-facility patient transfer has been published by the National Highway Traffic Safety Administration (NHTSA) and is available through their website (",
"    <a class=\"external\" href=\"file://www.nhtsa.gov/people/injury/ems/interfacility/index.htm\">",
"     file://www.nhtsa.gov/people/injury/ems/interfacility/index.htm",
"    </a>",
"    ). However, this guide does not specifically address pregnant patients. The",
"    <a class=\"external\" href=\"file://www.sogc.org/guidelines/public/165E-PS-October2005.pdf\">",
"     Society of Obstetricians and Gynaecologists of Canada",
"    </a>",
"    has published a Maternal Transport Policy Statement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870676\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, only 1.5 percent of all births are very low birthweight babies (VLBW, &lt;1500 g); however, a large proportion (51 percent) of neonatal mortality occurs in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In part for this reason, the March of Dimes published a document entitled &ldquo;Toward Improving the Outcome of Pregnancy,&rdquo; which stimulated the development of regionalized perinatal care systems and maternal transport programs. One of the primary purposes of regionalization was to clearly define the scope of neonatal care available at hospitals and increase the number of high-risk and premature births occurring at appropriate level facilities rather than transferring neonates to these facilities after birth. The benefit of this approach was subsequently illustrated by a meta-analysis that evaluated neonatal outcomes for VLBW or very preterm babies and found neonatal mortality significantly increased if delivery occurred outside of highly specialized (level III) hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/5\">",
"     5",
"    </a>",
"    ]. In the United States, 74 percent of VLBW deliveries between 2000 and 2008 occurred in high-risk facilities, but with wide variation among the states [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/6\">",
"     6",
"    </a>",
"    ]. Oregon had the highest rate of inborn VLBW neonates at 99.4 percent, compared with 32 percent in Mississippi. Only five states (Oregon, Nevada, Iowa, Rhode Island and Vermont) exceeded 90 percent.",
"   </p>",
"   <p>",
"    Although most maternal transports go to a facility with a well-defined level of neonatal care and for neonatal indications, some maternal transfers are for maternal indications; maternal levels of care are not as well-defined. Some experts have advocated establishment of national standards for regionalization of maternal-fetal-neonatal care in an effort to improve maternal morbidity, mortality and decrease &ldquo;near-misses&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/7\">",
"     7",
"    </a>",
"    ]. Some states, including Arizona and Indiana, have established obstetric levels of care for hospitals in addition to, and independent from, neonatal levels of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870888\">",
"    <span class=\"h1\">",
"     REGULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515544\">",
"    <span class=\"h2\">",
"     Emergency Medical Treatment and Active Labor Act (EMTALA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Emergency Medical Treatment and Active Labor Act (EMTALA) was enacted in 1986 to govern the transfer of unstable patients. It applies to all patients treated at facilities in the United States that accept payments from the Department of Health and Human Services (HHS), Centers for Medicare and Medicaid Services (CMS). The intent is to ensure that all patients receive a medical screening examination to evaluate for an emergent medical condition, which must be treated regardless of the patient&rsquo;s ability to pay. Under the statute, a pregnant woman who presents in active labor must be admitted and treated through delivery, unless an indication for transfer exists [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EMTALA guidelines require the following of hospitals with an emergency department:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide a medical screening examination to any individual who comes to the emergency department",
"     </li>",
"     <li>",
"      Provide necessary stabilizing treatment to any individual with an emergency medical condition or in labor",
"     </li>",
"     <li>",
"      Provide for appropriate transfer at patient request or if the facility does not have capability or capacity to provide necessary treatment to stabilize the emergency medical condition. The patient request for transfer must be in writing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an unstable patient is to be transferred, the treating physician is expected to document the reasons and that the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of the transfer favors patient transfer to a facility willing to accept the patient.",
"   </p>",
"   <p>",
"    Violations of the EMTALA statute may result in fines for hospitals and individual physicians, as well as termination of Medicare provider agreements or civil suits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515551\">",
"    <span class=\"h2\">",
"     Commission on Accreditation of Medical Transport Systems (CAMTS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Commission on Accreditation of Medical Transport Systems (CAMTS) is a voluntary accreditation program for medical transport services, including rotor wing (helicopter), fixed wing plane, and ground (ambulance), and is not specific to maternal transport. CAMTS has developed accreditation standards with measurable criteria for medical transport that are designed to address issues of patient care and safety. Accreditation is granted after completion of an application process and a site visit to evaluate &ldquo;substantial compliance&rdquo; with the accreditation standards [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CAMTS website describes the following general criteria for accreditation.",
"   </p>",
"   <p>",
"    General standards:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Capabilities and resources of the service",
"     </li>",
"     <li>",
"      Medical personnel",
"     </li>",
"     <li>",
"      Medical director",
"     </li>",
"     <li>",
"      Medical control physician",
"     </li>",
"     <li>",
"      Clinical care supervisor",
"     </li>",
"     <li>",
"      Staffing and physical requirements",
"     </li>",
"     <li>",
"      Mission types",
"     </li>",
"     <li>",
"      Initial and continuing education",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Aircraft/ambulance",
"      </span>",
"      section",
"     </li>",
"     <li>",
"      Medical configurations",
"     </li>",
"     <li>",
"      Operational issues",
"     </li>",
"     <li>",
"      Equipment",
"     </li>",
"     <li>",
"      Communications",
"     </li>",
"     <li>",
"      Management and administration",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Management/policies",
"      </span>",
"     </li>",
"     <li>",
"      Quality management",
"     </li>",
"     <li>",
"      Safety committee",
"     </li>",
"     <li>",
"      Infection control&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rotor wing standards:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Federal Aviation Administration (FAA) certificate",
"     </li>",
"     <li>",
"      Weather and weather minimums",
"     </li>",
"     <li>",
"      Pilot staffing and training",
"     </li>",
"     <li>",
"      Policies",
"     </li>",
"     <li>",
"      Maintenance",
"     </li>",
"     <li>",
"      Refueling",
"     </li>",
"     <li>",
"      Community outreach&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fixed wing standards:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FAA certificate",
"     </li>",
"     <li>",
"      Aircraft",
"     </li>",
"     <li>",
"      Weather",
"     </li>",
"     <li>",
"      Pilot staffing and training",
"     </li>",
"     <li>",
"      Policies",
"     </li>",
"     <li>",
"      Maintenance",
"     </li>",
"     <li>",
"      Refueling",
"     </li>",
"     <li>",
"      Community outreach&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ground inter-facility standards:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vehicles",
"     </li>",
"     <li>",
"      Qualifications of drivers",
"     </li>",
"     <li>",
"      Maintenance and sanitation",
"     </li>",
"     <li>",
"      Mechanic",
"     </li>",
"     <li>",
"      Policies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weather standards exist for air transport (helicopter and fixed wing), but not for ground transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515558\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATION FOR MATERNAL TRANSFER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870941\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transport of a pregnant patient from her present facility to another facility should be considered when the present facility does not have sufficient resources for maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neonatal care. Inter-facility agreements should be in place that formalize the relationship and clearly delineate responsibilities for the transferring and receiving facilities. A potential barrier to indicated transfer is the erroneous perception among providers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patients that the present facility can provide an appropriate level of care.",
"   </p>",
"   <p>",
"    The following are examples of conditions which may necessitate transfer.",
"   </p>",
"   <p>",
"    Maternal-fetal conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preterm labor",
"     </li>",
"     <li>",
"      Preterm premature rupture of membranes",
"     </li>",
"     <li>",
"      Hypertensive disorders of pregnancy, including eclampsia",
"     </li>",
"     <li>",
"      Bleeding due to an obstetrical condition",
"     </li>",
"     <li>",
"      Multiple gestation",
"     </li>",
"     <li>",
"      Fetal anomalies",
"     </li>",
"     <li>",
"      Fetal condition outside the scope of care of the neonatal care unit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal medical and surgical conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Infection/sepsis",
"      </span>",
"     </li>",
"     <li>",
"      Respiratory complications",
"     </li>",
"     <li>",
"      Cardiovascular disease, congenital or acquired",
"     </li>",
"     <li>",
"      Renal disease",
"     </li>",
"     <li>",
"      Connective tissue disorders",
"     </li>",
"     <li>",
"      Coagulopathy and complications of hemorrhage",
"     </li>",
"     <li>",
"      Neurologic abnormalities",
"     </li>",
"     <li>",
"      Liver disease",
"     </li>",
"     <li>",
"      Overdose",
"     </li>",
"     <li>",
"      Psychiatric emergencies",
"     </li>",
"     <li>",
"      Acute abdomen or peritonitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870926\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal transport may not be possible or advisable in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of an appropriate modality for safe maternal and neonatal transfer",
"     </li>",
"     <li>",
"      Weather and road conditions too hazardous for safe travel",
"     </li>",
"     <li>",
"      Maternal condition insufficiently stabilized (eg, persistent hemorrhage, severe hypertension)",
"     </li>",
"     <li>",
"      Delivery is anticipated before transport completed",
"     </li>",
"     <li>",
"      Neonate with a lethal condition",
"     </li>",
"     <li>",
"      Unstable fetal condition threatening to deteriorate rapidly (delay in delivery would result in death or damage to the fetus)",
"     </li>",
"     <li>",
"      Patient declines transfer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515572\">",
"    <span class=\"h1\">",
"     TRANSFER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transferring and receiving facilities each bear responsibilities in the transfer process. Both should have an understanding of, and operate within, all applicable local and state regulations, in addition to the federal statutes.",
"   </p>",
"   <p>",
"    Key components to the successful transport of a patient at risk for delivery include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good communication between the referring facility, transport team, and receiving facility. Written documentation or, ideally, recorded conversation with typed transcript.",
"     </li>",
"     <li>",
"      Timely",
"      <span class=\"nowrap\">",
"       response/arrival",
"      </span>",
"      by the transport team",
"     </li>",
"     <li>",
"      Experienced and trained transport personnel to assess patient status and determine appropriateness of transport",
"     </li>",
"     <li>",
"      Ability to provide a rapid mode of transport to the receiving facility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Providers at the transferring facility should initiate treatment and stabilization efforts prior to transport. At a minimum, this should include assessment of maternal vital signs, fetal condition, fetal position, and cervical examination if the patient is contracting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/11\">",
"     11",
"    </a>",
"    ]. All patients should have intravenous access with at least an 18-gauge catheter and should not be allowed oral intake. Foley catheter placement should be considered, depending on the patient condition and anticipated duration of transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870969\">",
"    <span class=\"h2\">",
"     Determining patient stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step before initiating transfer is to determine whether the mother and fetus are stable. According to the Emergency Medical Treatment and Active Labor Act (EMTALA) statute, stability for transfer is determined by the physician or qualified medical provider evaluating the patient. Stability is a judgment that the patient&rsquo;s condition is not expected to deteriorate substantially during the transfer process.",
"   </p>",
"   <p>",
"    According to the Centers for Medicare and Medicaid Services (CMS), a qualified medical provider may sign the certification that benefits of transfer outweigh the risks, in consultation with a physician, if the responsible physician is not physically present at time of transfer. Hospitals have the ability to designate non-physician medical providers to act as a qualified medical provider and provide medical screening examinations. If non-physicians will be screening patients, the hospital must indicate in their bylaws which non-physicians can perform this service; the written statute is not specific regarding whether the non-physician is a registered nurse, nurse practitioner, or certified nurse midwife. A clear process for phone consultation between the physician and non-physician provider and guidelines for when the physician must come in to assess the patient before transfer should be established. When a non-physician certifies the transfer, hospital bylaws should provide a means for physician signature to certify the transfer after the fact.",
"   </p>",
"   <p>",
"    In the event the patient is unstable (ie, in active labor), the transferring physician must document that the benefits of transfer to another facility outweigh the risks for the mother",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the fetus.",
"   </p>",
"   <p>",
"    Although delivery of the obstetric patient during transport is a significant concern, the available data suggest that delivery en route is a rare event. In one large study, 1080 obstetric transports for preterm labor were performed in nulliparous and multiparous patients during a 21-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/12\">",
"     12",
"    </a>",
"    ]. Fifty-four patients were &gt;7 cm dilation at the time of the call for transport, and 25 of the 54 were fully dilated; station ranged from -2 (12 patients) to +2 (10 patients). A trained flight nurse evaluated each patient at the referring facility to determine safety of transport, and decided not to transport 5 of the 54 patients. Of the remaining 49 patients, 40 were transported by helicopter with a mean transport time of 15 minutes, 8 were transported by fixed wing transport with a mean travel time of 90 minutes, and 1 was transported by ground ambulance with a transport time of 27 minutes. No patient delivered en route, but 32 (59 percent) delivered within 0 to 120 minutes of arrival at the receiving hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870977\">",
"    <span class=\"h2\">",
"     Records and documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Written informed consent should be obtained and a copy of the patient&rsquo;s medical records (eg, antenatal record, pertinent hospital records and ultrasound reports) should accompany the patient. Reports that are unavailable at the time of transport can be faxed when available. Completion of a transfer form that includes key information about the patient, the indication for transport, and mode of transport selected is also recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25870992\">",
"    <span class=\"h2\">",
"     Communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Written patient care guidelines and ongoing communication between providers at each facility are important to facilitate safe transfer. Once the decision to transfer has been made, the transferring facility (physician or provider performing the medical screening examination) should contact the receiving facility. Key points the transferring provider should communicate include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient",
"      <span class=\"nowrap\">",
"       medical/obstetrical",
"      </span>",
"      history",
"     </li>",
"     <li>",
"      Gestational age",
"     </li>",
"     <li>",
"      Indication for transfer",
"     </li>",
"     <li>",
"      Stability of patient (ie, vital signs, cervical exam, and fetal heart rate interpretation)",
"     </li>",
"     <li>",
"      Intended mode of transport",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The receiving facility should clearly communicate its willingness to accept the patient in transport. After the patient has been transferred, the receiving facility should provide follow-up on the patient, as well as a written discharge summary with recommendations for outpatient care upon discharge. The process for communicating this information to the transferring",
"    <span class=\"nowrap\">",
"     facility/provider",
"    </span>",
"    and the person responsible for this communication (eg, receiving physician) should be clearly defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25871007\">",
"    <span class=\"h2\">",
"     Responsibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The referring physician and hospital have continuing responsibility for the patient until the patient arrives at the receiving facility, unless the receiving facility is sending the transport team. In that instance, the receiving facility assumes responsibility for the patient once she leaves the transferring hospital.",
"   </p>",
"   <p>",
"    Most transport teams do not include a physician. If the transport team is not able to manage the medical issues in transport with phone consultation, then stability for transport should be reconsidered. However, in some circumstances, an unstable patient must be transferred to another facility and may necessitate physician presence. For example, a postpartum patient may require emergency neurologic care for an intracranial hemorrhage that occurred at a facility unable to provide those services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515579\">",
"    <span class=\"h2\">",
"     Equipment and supplies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment needed for transport will depend on the type of transport, patient acuity, the type of vehicle utilized, and the distance of the transfer. The minimum general equipment required should be that needed to asses maternal vital signs, perform resuscitation if indicated, including acute airway management, availability of portable oxygen tanks and necessary equipment for their use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/11\">",
"     11",
"    </a>",
"    ]. The following specific items may be considered.",
"   </p>",
"   <p>",
"    General equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stethoscope",
"     </li>",
"     <li>",
"      Sphygmomanometer",
"     </li>",
"     <li>",
"      Thermometer",
"     </li>",
"     <li>",
"      Reflex hammer",
"     </li>",
"     <li>",
"      Emesis basin",
"     </li>",
"     <li>",
"      Flashlight",
"     </li>",
"     <li>",
"      Doppler device for fetal heart rate assessment",
"     </li>",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      Peripads",
"     </li>",
"     <li>",
"      Sterile lubricant",
"     </li>",
"     <li>",
"      Antiseptic solution (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      or povidone-iodine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous (IV) equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lactate ringers, normal saline, or dextrose solutions",
"     </li>",
"     <li>",
"      IV starting kits and tubing",
"     </li>",
"     <li>",
"      IV catheters (16- and 18-gauge)",
"     </li>",
"     <li>",
"      Alcohol pads",
"     </li>",
"     <li>",
"      Adhesive tape",
"     </li>",
"     <li>",
"      Infusion pump",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adult airway and resuscitation equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxygen tank and mask",
"     </li>",
"     <li>",
"      Oral airway",
"     </li>",
"     <li>",
"      Laryngoscope handle and blades",
"     </li>",
"     <li>",
"      Endotracheal tubes and stylets",
"     </li>",
"     <li>",
"      Suction equipment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"     </li>",
"     <li>",
"      Oxytocin",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       Hydralazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       Indomethacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      hydrochloride",
"     </li>",
"     <li>",
"      Methergine",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       Naloxone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"       Calcium gluconate",
"      </a>",
"     </li>",
"     <li>",
"      Plasma expanders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency delivery equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bulb syringe",
"     </li>",
"     <li>",
"      Scissors",
"     </li>",
"     <li>",
"      Cord clamp",
"     </li>",
"     <li>",
"      Hemostats or Kelly clamps",
"     </li>",
"     <li>",
"      Gauze",
"     </li>",
"     <li>",
"      Gloves",
"     </li>",
"     <li>",
"      Plastic bag or basin for placenta",
"     </li>",
"     <li>",
"      Towels and blankets",
"     </li>",
"     <li>",
"      Mylar emergency blanket",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infant resuscitation equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxygen masks in premature and neonate sizes",
"     </li>",
"     <li>",
"      Neonatal laryngoscope and endotracheal tubes with stylets and connectors",
"     </li>",
"     <li>",
"      Neonatal stethoscope",
"     </li>",
"     <li>",
"      Infant suction catheters",
"     </li>",
"     <li>",
"      Epinephrine 1:10,000 concentration",
"     </li>",
"     <li>",
"      1 and 2 mL syringes",
"     </li>",
"     <li>",
"      20- and 25-gauge needles",
"     </li>",
"     <li>",
"      Orogastric feeding tubes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515586\">",
"    <span class=\"h2\">",
"     Mode of transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;In determining the mode of transport, the referring provider must take into consideration a variety of factors, including availability of different modes of transport, patient acuity, weather, distance, time, ground conditions, and cost. Utilizing fixed wing and helicopter transport obviously requires additional resources, particularly take-off and landing sites. Fixed wing (or in some cases, helicopter) transport also involves additional transfer of the patient by ground ambulance from the landing site to the hospital facility.",
"   </p>",
"   <p>",
"    Limited observational data are available regarding advantages and disadvantages of various transport modes for obstetric patients. Air medical transport of pregnant women by helicopter or fixed wing plane appears to be safe and associated with a very low risk of in-flight complication(s), including delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial prenatal assessment and patient education\", section on 'Airline travel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Helicopter transport offers some advantages compared to ground transport, particularly when the distance to the receiving facility is relatively long or in urban areas where traffic congestion prevents rapid transit. In these situations, some patients not felt to be stable for ground transport may be candidates for more rapid transfer by helicopter. Helicopter transport costs can be competitive with ground transport costs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515593\">",
"    <span class=\"h2\">",
"     Transport team personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Composition of the maternal transport team has not been standardized nationally. Team composition is somewhat limited by the physical capacity of the transport vehicle; therefore, the team members should have advanced skill sets and experience.",
"   </p>",
"   <p>",
"    A Maternal Transport Program funded and administered through the Arizona Department of Health Services (ADHS) provides a good example of the composition and training of a maternal transport team [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/18\">",
"     18",
"    </a>",
"    ]. In this program:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All maternal transports are accomplished by a team of providers consisting of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An experienced, trained registered nurse (RN) team leader",
"     </li>",
"     <li>",
"      An experienced, trained secondary team member (ie, flight nurse, respiratory therapist, or paramedic with specialty training)",
"     </li>",
"     <li>",
"      Additional personnel such as a physician or nurse practitioner, as needed on a case-by-case basis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimum recommended skills of the transport team include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Detailed physical examination and assessment of pregnant patient",
"     </li>",
"     <li>",
"      Newborn assessment and resuscitation",
"     </li>",
"     <li>",
"      Advanced airway management of adult and newborn",
"     </li>",
"     <li>",
"      Maternal vaginal examination and sterile speculum examination",
"     </li>",
"     <li>",
"      Bladder catheter and intravenous (IV) placement",
"     </li>",
"     <li>",
"      Ability to administer tocolytic agents, antihypertensives, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"     </li>",
"     <li>",
"      Fetal heart rate monitoring and interpretation",
"     </li>",
"     <li>",
"      Emergency vaginal delivery",
"     </li>",
"     <li>",
"      Understanding of maternal physiology and common disease processes",
"     </li>",
"     <li>",
"      Ability to communicate effectively and professionally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All team members performing maternal transport should maintain Advanced Cardiac Life Support (ACLS) certification, complete the Neonatal Resuscitation Program (NRP) training every two years, and receive education regarding fetal heart rate tracing interpretation. If the transport team will be participating in air transport, then additional education and orientation to general aviation and safety are recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29995781\">",
"    <span class=\"h2\">",
"     En route care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing assessment and documentation of the maternal and fetal condition is an important component of a safe transport. Maternal vital signs should be obtained and recorded every 15 minutes, or more frequently, as dictated by the patient&rsquo;s condition. The frequency of uterine contractions should be noted and documented. The patient should be transported in a left lateral decubitus or sitting position to minimize aortocaval compression from the uterus.",
"   </p>",
"   <p>",
"    Patients may develop nausea or anxiety related to the transport. Supportive care should be provided.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     Ondansetron",
"    </a>",
"    4 to 8 mg intravenously (IV) will provide antiemetic relief;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    25 to 50 mg IV offers the advantage of a sedative effect (if desired) in addition to the antiemetic effect.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    1 to 2 mg IV may be used alone or in combination with an antiemetic for patients with more significant anxiety issues.",
"   </p>",
"   <p>",
"    The ability to perform en route continuous electronic fetal heart rate monitoring can be limited by available space for the monitor, early gestational age, and turbulence or movement from the transport process. Intermittent documentation of fetal heart tones by Doppler should be performed if continuous fetal monitoring cannot be accomplished, and is an acceptable alternative (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link&amp;anchor=H4#H4\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Equipment and techniques'",
"    </a>",
"    ). Possible interventions if a nonreassuring fetal heart rate is identified en route include repositioning the patient, increasing intravenous fluid administration, and administering supplemental oxygen or tocolytic drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38311?source=see_link\">",
"     \"Management of intrapartum category I, II, and III fetal heart rate tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data exist regarding fetal monitoring during maternal transport. In the only study on the feasibility of continuous electronic fetal heart rate monitoring during maternal fixed wing transport, 40 of the 57 transports (70 percent) were electronically monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9128/abstract/19\">",
"     19",
"    </a>",
"    ]. The other 17 patients could not be monitored electronically because of obesity, no electronic monitor available, unable to convert monitor for use with an airplane battery, or &lsquo;unknown&rsquo; reasons; the fetal heart rate of these patients was intermittently monitored with a Doppler device. Thirty-three of the 40 electronic fetal heart rate tracings (83 percent) were clear and readable at least 50 percent of the time en route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515600\">",
"    <span class=\"h1\">",
"     SYNOPSIS OF MANAGEMENT IN SELECTED CLINICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following outlines provide a synopsis of our approach to maternal assessment and preparation for transfer in some common clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29994719\">",
"    <span class=\"h2\">",
"     Preterm labor",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain maternal vital signs and assess fetal status",
"     </li>",
"     <li>",
"      Perform a vaginal exam if intact membranes",
"     </li>",
"     <li>",
"      Determine fetal presentation",
"     </li>",
"     <li>",
"      Test for fetal fibronectin (fFN) if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link\">",
"       \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Screen for gonorrhea and chlamydia if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44807?source=see_link&amp;anchor=H21417087#H21417087\">",
"       \"Prenatal care (after initial prenatal assessment)\", section on 'Sexually transmitted disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Check urinalysis (sterile catheterized specimen preferred)",
"     </li>",
"     <li>",
"      Obtain Group B Streptococcus (GBS) culture and initiate GBS prophylaxis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for fetal neuroprotection if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=see_link\">",
"       \"Neuroprotective effects of in utero exposure to magnesium sulfate\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer tocolysis if clinically indicated because of labor, particularly preterm labor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"       \"Inhibition of acute preterm labor\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      12 mg intramuscular (IM) prior to transport if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29994726\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain maternal vital signs and assess fetal status",
"     </li>",
"     <li>",
"      Perform sterile speculum exam for pooling and microscopic exam for ferning. Nitrazine testing alone is not sufficient. Specific point-of-care tests may also be performed (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H6#H6\">",
"       \"Preterm premature rupture of membranes\", section on 'Diagnostic evaluation'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Assess cervical dilation visually at the time of sterile speculum exam",
"     </li>",
"     <li>",
"      Determine fetal presentation",
"     </li>",
"     <li>",
"      Do not perform digital vaginal exam unless clinically indicated. If delivery is believed to be imminent, a speculum to assess cervical dilatation is usually sufficient.",
"     </li>",
"     <li>",
"      Assess for clinical evidence of chorioamnionitis (eg, malodor, fever, uterine tenderness, contractions, fetal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      maternal tachycardia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H12#H12\">",
"       \"Preterm premature rupture of membranes\", section on 'Management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      12 mg IM prior to transport if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"       \"Preterm premature rupture of membranes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H16#H16\">",
"       \"Preterm premature rupture of membranes\", section on 'Antenatal corticosteroids'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Initiate intravenous (IV) antibiotics prior to transport if clinically indicated for prophylaxis or treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H17#H17\">",
"       \"Preterm premature rupture of membranes\", section on 'Antibiotics'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for fetal neuroprotection if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=see_link\">",
"       \"Neuroprotective effects of in utero exposure to magnesium sulfate\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer tocolysis if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H22#H22\">",
"       \"Preterm premature rupture of membranes\", section on 'Tocolysis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29994741\">",
"    <span class=\"h2\">",
"     Third trimester vaginal bleeding",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain maternal vital signs and assess fetal status",
"     </li>",
"     <li>",
"      Do not perform a vaginal exam until placenta previa has been ruled out by ultrasound (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=see_link\">",
"       \"Management of placenta previa\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Determine fetal presentation",
"     </li>",
"     <li>",
"      Assess for cause of bleeding (eg, previa, abruption, labor, trauma) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\", section on 'Second and third trimester bleeding'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Estimate total blood loss and potential for on-going hemorrhage",
"     </li>",
"     <li>",
"      Check maternal hemoglobin and hematocrit",
"     </li>",
"     <li>",
"      Document any blood products transfused",
"     </li>",
"     <li>",
"      Maintain more than one IV site (one with 16-gauge catheter, if possible)",
"     </li>",
"     <li>",
"      Place a bladder catheter to monitor urine output",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for fetal neuroprotection if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=see_link\">",
"       \"Neuroprotective effects of in utero exposure to magnesium sulfate\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer tocolysis if clinically indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=see_link&amp;anchor=H8#H8\">",
"       \"Management of placenta previa\", section on 'Tocolysis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=see_link&amp;anchor=H7#H7\">",
"       \"Placental abruption: Management\", section on 'Management'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29994748\">",
"    <span class=\"h2\">",
"     Pregnancy-related hypertensive disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess maternal symptoms of headache, scotomata, epigastric pain, nausea and vomiting",
"     </li>",
"     <li>",
"      Obtain maternal vital signs and assess fetal status",
"     </li>",
"     <li>",
"      Administer a loading dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      prior to transport (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link&amp;anchor=H16#H16\">",
"       \"Preeclampsia: Management and prognosis\", section on 'Seizure prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H12#H12\">",
"       \"Eclampsia\", section on 'Treatment of convulsions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Place a bladder catheter and monitor intake and output to avoid excessive fluid administration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link&amp;anchor=H961072#H961072\">",
"       \"Preeclampsia: Management and prognosis\", section on 'Fluids'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Provide supplemental oxygen to maintain O",
"      <sub>",
"       2",
"      </sub>",
"      saturation &ge;95 percent",
"     </li>",
"     <li>",
"      Perform laboratory evaluation for transaminases (aspartate transaminase [AST], alanine transaminase [ALT]), platelet count, hemoglobin, hematocrit, creatinine, and proteinuria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H18#H18\">",
"       \"Preeclampsia: Clinical features and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H1567356#H1567356\">",
"       \"Preeclampsia: Clinical features and diagnosis\", section on 'Post-diagnostic evaluation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Document reflexes, edema, visual acuity",
"     </li>",
"     <li>",
"      Institute seizure precautions",
"     </li>",
"     <li>",
"      Treat anxiety with an anxiolytic, as needed",
"     </li>",
"     <li>",
"      Assess for signs and symptoms of severe disease (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer antihypertensive medications if hypertension is severe (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of hypertension in pregnant and postpartum women\", section on 'Preeclampsia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Manage seizure activity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H9#H9\">",
"       \"Eclampsia\", section on 'Management'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21515622\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal transport should be considered if the facility does not have sufficient resources to meet maternal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neonatal medical needs. (See",
"      <a class=\"local\" href=\"#H21515558\">",
"       'Indications and contraindication for maternal transfer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outcomes for premature neonates are improved if delivery occurs at an appropriate level facility versus neonatal transport to the appropriate facility. (See",
"      <a class=\"local\" href=\"#H25870676\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The maternal transport should be coordinated between the transferring and receiving facility and the patient accompanied by appropriately trained medical personnel. (See",
"      <a class=\"local\" href=\"#H21515572\">",
"       'Transfer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An understanding of, and compliance with, the Emergency Medical Treatment and Active Labor Act (EMTALA) guidelines and relevant state statutes is essential when transporting patients. (See",
"      <a class=\"local\" href=\"#H25870888\">",
"       'Regulations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/1\">",
"      Hohlagschwandtner M, Husslein P, Klebermass K, et al. Perinatal mortality and morbidity. Comparison between maternal transport, neonatal transport and inpatient antenatal treatment. Arch Gynecol Obstet 2001; 265:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/2\">",
"      Wilson AK, Martel MJ, Arsenault MY, et al. Maternal transport policy. J Obstet Gynaecol Can 2005; 27:956.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/nchs/data/hpdata2010/hp2010_final_review.pdf. (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/4\">",
"      Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2000 period linked birth/infant death data set. Natl Vital Stat Rep 2002; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/5\">",
"      Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2000 period linked birth/infant death data set. Natl Vital Stat Rep 2002; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://mchb.hrsa.gov/grants/natlperformmeasure17rpt.pdf. (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/7\">",
"      Hankins GD, Clark SL, Pacheco LD, et al. Maternal mortality, near misses, and severe morbidity: lowering rates through designated levels of maternity care. Obstet Gynecol 2012; 120:929.",
"     </a>",
"    </li>",
"    <li>",
"     Data from Emergency Medical Treatment and Labor Act. P.L. 99-272, 100 Stat.164 (1986) codified at 42 U.S.C. SS 1395dd et seq (2010). file://www.gpo.gov/fdsys/ pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap7-subchapXVIII.pdf. Retrieved November 16, 2012. (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     file://www.cms.gov/Regulations-and Guidance/Guidance/Transmittals/downloads/R46SOMA.pdf. (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     file://www.camts.org/Stds_Approved_EditedLL8-30-12.pdf. (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     Maternal and Neonatal Interhospital Transfer. In: Guidelines for Perinatal Care, 7th ed, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/12\">",
"      Elliott JP, Sipp TL, Balazs KT. Maternal transport of patients with advanced cervical dilatation--to fly or not to fly? Obstet Gynecol 1992; 79:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/13\">",
"      Connor SB, Lyons TJ. U.S. Air Force aeromedical evacuation of obstetric patients in Europe. Aviat Space Environ Med 1995; 66:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/14\">",
"      Elliott JP, Foley MR, Young L, et al. Air transport of obstetric critical care patients to tertiary centers. J Reprod Med 1996; 41:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/15\">",
"      Van Hook JW, Leicht TG, Van Hook CL, et al. Aeromedical transfer of preterm labor patients. Tex Med 1998; 94:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/16\">",
"      Ohara M, Shimizu Y, Satoh H, et al. Safety and usefulness of emergency maternal transport using helicopter. J Obstet Gynaecol Res 2008; 34:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/17\">",
"      Elliott JP, O'Keeffe DF, Freeman RK. Helicopter transportation of patients with obstetric emergencies in an urban area. Am J Obstet Gynecol 1982; 143:157.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.azdhs.gov/phs/owch/pdf/highrisk/FY2009HRPPPolicyandProcedureManual.pdf. (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9128/abstract/19\">",
"      Elliott JP, Trujillo R. Fetal monitoring during emergency obstetric transport. Am J Obstet Gynecol 1987; 157:245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17178 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9128=[""].join("\n");
var outline_f8_58_9128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21515622\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21515537\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25870676\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25870888\">",
"      REGULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21515544\">",
"      Emergency Medical Treatment and Active Labor Act (EMTALA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21515551\">",
"      Commission on Accreditation of Medical Transport Systems (CAMTS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21515558\">",
"      INDICATIONS AND CONTRAINDICATION FOR MATERNAL TRANSFER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25870941\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25870926\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21515572\">",
"      TRANSFER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25870969\">",
"      Determining patient stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25870977\">",
"      Records and documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25870992\">",
"      Communication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25871007\">",
"      Responsibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21515579\">",
"      Equipment and supplies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21515586\">",
"      Mode of transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21515593\">",
"      Transport team personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29995781\">",
"      En route care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21515600\">",
"      SYNOPSIS OF MANAGEMENT IN SELECTED CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29994719\">",
"      Preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29994726\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29994741\">",
"      Third trimester vaginal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29994748\">",
"      Pregnancy-related hypertensive disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21515622\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/17178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/17178|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/60/43979\" title=\"table 1\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38311?source=related_link\">",
"      Management of intrapartum category I, II, and III fetal heart rate tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=related_link\">",
"      Management of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=related_link\">",
"      Neuroprotective effects of in utero exposure to magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=related_link\">",
"      Placental abruption: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44807?source=related_link\">",
"      Prenatal care (after initial prenatal assessment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_58_9129="Molecular pathology of the thalassemic syndromes";
var content_f8_58_9129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular pathology of the thalassemic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9129/contributors\">",
"     Edward J Benz, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9129/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9129/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/58/9129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deficiencies in hemoglobin biosynthesis that characterize the various forms of thalassemia arise from mutations in or near the two globin gene clusters which encode the globin polypeptide subunits of hemoglobin. To date, no forms of thalassemia arising primarily from defects in iron or heme metabolism have been described. All known forms are due to inherited defects in the biosynthesis or post-translational stability of the globin subunits themselves.",
"   </p>",
"   <p>",
"    Because of their small size, their arrangement into relatively compact gene clusters, and their well characterized physiology, pathology, and clinical genetics, the globin genes were the first human genes to be cloned and thoroughly characterized. The mutations that cause the thalassemia syndromes were the first to be defined at the level of their DNA structure. Indeed, the delineation of the impact of these mutations on mRNA and protein expression provided the paradigm for the identification of mutations causing other diseases.",
"   </p>",
"   <p>",
"    The molecular pathology of the thalassemic syndromes will be discussed here. This subject is best understood from the perspective of the normal structure and function of the genes encoding the individual globins [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/1\">",
"     1",
"    </a>",
"    ]. The first section of this review will outline the essential features of normal hemoglobin biosynthesis and its underlying molecular biology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second section will discuss illustrative examples of the over 100 different mutations causing thalassemia and explain their effects on globin synthesis. The pathophysiologic and clinical aspects of the thalassemic syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107740994\">",
"    <span class=\"h1\">",
"     CLINICAL RELEVANCE OF THE MOLECULAR BASIS OF THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The globin gene clusters and their RNA and globin protein products are the most thoroughly understood in the human genome at the level of their basic structure and arrangement; regulated expression during embryonic, fetal, and adult life; structure-function relationships of the globin proteins; and physiology and pathophysiology of conditions arising from alterations in the genes or elements that control them.",
"   </p>",
"   <p>",
"    The alpha and beta globin gene clusters are small and compact, such that molecular analysis of them at the sequence level is readily performed. Thus, any clinician confronted with findings suggestive of a hemoglobinopathy should consult with their clinical pathology laboratory about getting direct analysis of the hemoglobin profile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    globin gene profile that might aid diagnosis. Very few labs possess this capability locally but nearly all maintain a connection to a reference laboratory. In this author&rsquo;s experience, these reference labs also do a good job of guiding interpretation of the results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOBIN GENE ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genes coding for the individual human globins are located in two clusters (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"beta gene\" cluster, located on the terminal portion of the short arm of chromosome 11 (p15), is about 70 kilobases long. It contains the embryonic (epsilon), fetal (A(gamma) and G(gamma)) and adult (delta and beta) globin genes coding for the \"beta\" (or non-alpha) sub-unit components.",
"     </li>",
"     <li>",
"      The 40 kb \"alpha gene\" cluster, located on the short arm of chromosome 16, contains the embryonic (zeta) and two copies (alpha-2 and alpha-1) of the",
"      <span class=\"nowrap\">",
"       fetal/adult",
"      </span>",
"      (alpha) gene encoding the \"alpha\" component. While the alpha globins produced by these two genes are identical, the alpha-2 gene is expressed more efficiently than the alpha-1 gene, so that abnormalities of the alpha-2 gene are more apt to be clinically apparent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within each gene cluster, the structural genes are separated on both their 3' and 5' ends by variable stretches of non-coding DNA containing several types of regulatory sequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Promoter elements are essential for the binding of messenger RNA polymerase and the initiation of transcription.",
"     </li>",
"     <li>",
"      Enhancer and silencer elements stimulate or repress transcriptional activity depending on the array of proteinaceous \"transcription factors\" to which they are bound.",
"     </li>",
"     <li>",
"      Stage selector elements facilitate switching from embryonic to fetal to adult hemoglobin; they may represent specialized enhancer and silencer sequences.",
"     </li>",
"     <li>",
"      The Locus Control Region (LCR) functions as a \"master switch.\" Both globin gene clusters possess a LCR, located many kilobases upstream of the structural loci (",
"      <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"       figure 1",
"      </a>",
"      ). The LCR appears to interact with a combination of transcription factors at the onset of erythroid maturation in such a way as to enhance access of the transcriptional machinery and other transcriptional factors to the promoters, enhancers, and silencers within the gene complex. In this sense, some regard the LCR as a \"super enhancer.\" LCR function is absolutely required for expression of globin genes at the extraordinary high levels needed to support normal hemoglobin production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal hemoglobin biosynthesis requires an intact structural gene and the structural and spatial integrity of silencers, enhancers, promoters, and LCR sequences. Despite considerable effort, we do not fully understand how the sequences and factors regulating globin gene expression interact with one another to ensure high levels of expression of the proper globins at the proper developmental stage and during the proper steps of erythroid differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Non-globin locus mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all of the mutations causing thalassemia reside in or near the globin locus, but at least two interesting exceptions have been reported with the GATA-1 and ATRX genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     GATA-1 mutations and beta thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;GATA-1 is a transcription factor on the X chromosome that is important for activating many genes during erythropoiesis, including globin genes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/2\">",
"     2",
"    </a>",
"    ]. In individuals with the R216Q mutation, beta thalassemia occurs in conjunction with thrombocytopenia and dyserythropoietic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The basis for selective impairment of the beta locus in the two involved families is unclear but may be related to the impact of the mutation on an interacting factor called \"friend of GATA-1\" (FOG-1), or other as yet unknown factors that affect the activation of the beta globin gene disproportionately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H10#H10\">",
"     \"Regulation of erythropoiesis\", section on 'GATA-1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     ATRX mutations and alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations affecting the ATRX gene on the X chromosome are associated with the alpha",
"    <span class=\"nowrap\">",
"     thalassemia/mental",
"    </span>",
"    retardation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/5\">",
"     5",
"    </a>",
"    ]. The protein product of this gene affects broad patterns of gene transcription and participates in epigenetic remodeling of chromatin.",
"   </p>",
"   <p>",
"    Somatic mutations of this locus appear to account for at least some of the cases of acquired alpha thalassemia (also called acquired hemoglobin H disease) encountered in a subset of patients with myelodysplastic syndromes and more rarely in AML and other myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Of interest, most of those affected have been elderly men [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4008672#H4008672\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Acquired hemoglobin H disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transcription into messenger RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alpha-like genes are 1100 bases long, and beta-like genes, about 1800 bases long. Each contains three exons, ultimately coding for globin messenger RNA (mRNA). The exons are separated by two introns, which are transcribed into the mRNA precursor but subsequently excised by pre-mRNA splicing. Splicing knits the exons together in precise register, producing the functional mRNA.",
"   </p>",
"   <p>",
"    Intranuclear processing of globin mRNA includes the addition of a \"cap\" structure at the 5' end of the mRNA molecules, and a stretch of adenylate (A) residues (the \"poly-A tail\") at the 3' end. The 5' cap facilitates efficient translation of the mRNA nucleotide sequence into the amino acid sequence of the globin polypeptide, while the poly-A tail promotes mRNA stability.",
"   </p>",
"   <p>",
"    The fully spliced and modified globin mRNA is transported from nucleus to cytoplasm. Once regarded as a passive process of diffusion, mRNA transport is now known to be a complex, energy consuming, and, probably, regulated process. No forms of thalassemia due to primary defects in mRNA transport have been described. However, impaired mRNA transport may be a secondary abnormality that contributes to reduced accumulation of certain thalassemic globin mRNAs with impaired splicing or translational capacity.",
"   </p>",
"   <p>",
"    The amount of protein arising from the activity of a globin gene depends on three interacting cytoplasmic processes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      the amount of mature mRNA delivered to the cytoplasm",
"     </li>",
"     <li>",
"      the rate of mRNA translation into proteins by polyribosomes",
"     </li>",
"     <li>",
"      the rate at which mRNA is degraded",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the case of normal human globin genes, virtually all of the initial pre-mRNA transcripts are delivered in fully functional spliced form to the cytoplasm as mature globin mRNA. The critical need for an equal balance of alpha and non-alpha globin synthesis appears to be met largely by the inherent maximal activity of the alpha and non-alpha genes expressed at each stage of ontogeny. This appears to be assured by nearly equal rates of alpha and beta-like mRNA transcription. However, as will be discussed below, equal synthesis of alpha and beta globin protein depends on the interplay between the individual translational efficiencies and stabilities of alpha and beta-like mRNAs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     mRNA stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal globin mRNAs are extraordinarily long lived. While the typical half-life of most mammalian mRNAs is less than six hours, alpha globin mRNA has a half-life of about 30 hours, while that of beta globin mRNA is 15 to 20 hours. Delta globin mRNA is much shorter lived, with a half-life of 3.5 hours, a feature that probably explains why the anucleate circulating reticulocytes, which retain only mRNA synthesized one to two days earlier at the erythroblast stage, produce no new delta globin chains. Gamma, epsilon, and zeta mRNAs appear to have stabilities about the same, or slightly less, than that of beta globin mRNA.",
"   </p>",
"   <p>",
"    The extraordinary stability of globin messenger RNAs resides in stabilizing sequences located in the 3' untranslated sequences (3' UTR) of the mRNA molecule. These stabilizer elements, best characterized for human alpha globin mRNA, bind to proteins which confer resistance to nucleolytic cleavage. Forms of thalassemia resulting from mutations of these sequences have not been described. However, certain forms of alpha thalassemia, of which hemoglobin Hb Constant Spring is the prototype, exhibit markedly reduced stability, due to secondary disruption of the interactions between 3' UTR stabilizer sequences and their binding proteins (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Failed translation termination: Hb constant spring'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Translation into globin protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Translation initiation is the process by which the ribosome attaches itself near the 5' end of the mRNA molecule and aligns its translational machinery in a proper reading frame so that the mRNA is translated into the intended sequence of amino acids. Messenger RNA translation is an extraordinarily complex process. The rate limiting step for translation of globin mRNAs is \"initiation\"; normal translation requires an initiator methionine codon, a continuously open \"reading frame\" (ie, each three base codon read in succession downstream of the initiator codon codes for an amino acid), and a normally positioned translation termination codon or \"nonsense\" codon (UAA, UAG, UGA) which codes for no amino acid but specifies instead the place at which translation should stop.",
"   </p>",
"   <p>",
"    The initiator codon (AUG) is the essential signal required to mark, for the ribosome, the precise base at which translation of succeeding triplet codons in the open reading frame should commence. Translation will stop when a nonsense codon is reached. Mutations which convert \"sense\" to \"nonsense\" codons will result in production of a truncated globin peptide which may or may not accumulate as a stable protein product.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The beta-like globin polypeptide is 146 amino acids long, not including the initiator methionine, which is cleaved during the translation; the opening reading frame must thus have 147 consecutive \"sense\" codons, or 441 bases in the open reading frame (ORF). Beta-like globin mRNAs are translated more efficiently than alpha-like globin mRNAs. This appears to reflect differences in the 5' untranslated sequences (5' UTRs) of the individual mRNAs since, if the 5' UTRs of alpha and beta globin mRNA are interchanged, their translational efficiencies change accordingly.",
"     </li>",
"     <li>",
"      Alpha-like globins are 141 amino acids long, requiring an open reading frame of 142 codons, or 426 bases. Normal erythroid progenitors contain slightly more alpha-like globin mRNA than beta-like globin mRNA. This probably reflects the slightly longer half-lives of alpha-like globin mRNAs (see",
"      <a class=\"local\" href=\"#H7\">",
"       'mRNA stability'",
"      </a>",
"      above), and, possibly, a slight excess of alpha globin mRNA transcription.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences in translation and mRNA amount appear to balance each other, so that virtually equal amounts of alpha-like and beta-like globin are synthesized in normal erythroid cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hemoglobin assembly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final steps required for normal hemoglobin production are the post-translational assembly of the four globin chains with four heme molecules and their interaction with one another to form functioning hemoglobin tetramers and ensure their continued stability in the cell.",
"   </p>",
"   <p>",
"    This process may be facilitated by the presence of two proteins, alpha-hemoglobin stabilizing protein (AHSP), and heme-regulated eIF2alpha kinase (HRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha-hemoglobin stabilizing protein (AHSP) is a chaperone protein which forms a reversible complex with free alpha hemoglobin chains [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/11\">",
"       11",
"      </a>",
"      ], preventing the formation of free (excess) alpha chains, inhibiting the production of cytotoxic reactive oxygen species, and stabilizing nascent alpha chains for hemoglobin assembly [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/12-16\">",
"       12-16",
"      </a>",
"      ]. The physiologically relevant replacement of the chaperone AHSP protein by beta hemoglobin chains then leads to the production of the alpha-beta dimer [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/17\">",
"       17",
"      </a>",
"      ], two of which combine to produce the final hemoglobin tetramer, most likely non-enzymatically. Loss, decreased levels, or polymorphisms of AHSP may exacerbate beta thalassemia, a condition in which alpha chains are made in excess [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/13,18,19\">",
"       13,18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heme-regulated alpha-subunit of eukaryotic translational initiation factor 2 (eIF2alpha) kinase (HRI) prevents the accumulation of excess alpha- and beta-globin in the absence of heme. Its presence has been shown to reduce the severity of beta thalassemia in mice; the disorder is embryonic lethal in its absence [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experiments in a murine model of beta thalassemia have also suggested that excess alpha chains may be removed by protein quality-control pathways such as ubiquitin-mediated proteolysis and autophagy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The resulting hemoglobin tetramers are extraordinarily stable; nearly all of hemoglobin formed during erythropoiesis remains intact in the red cell throughout its 120-day circulating life span. Some forms of thalassemia arise from mutations that disrupt the formation of the intact tetramer or its stability after formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MOLECULAR LESIONS CAUSING THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalassemias result when mutations cause selective deficiencies in the synthesis of alpha-like or beta-like globin. However, it is the",
"    <strong>",
"     imbalance",
"    </strong>",
"    in accumulation of globin subunits that leads to formation of inclusion bodies from unpaired globin chains and the consequent pathophysiology of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .) The discussion that follows considers only alpha and beta thalassemias in detail; delta, gamma, epsilon, and zeta thalassemias are rare and usually not associated with significant disease in adults. A few instructive exceptions will be included.",
"   </p>",
"   <p>",
"    Several hundred mutations causing thalassemia have been described to date [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/22\">",
"     22",
"    </a>",
"    ]. These affect every step in globin gene expression, including the presence and spatial arrangement of the globin gene complex, transcription, pre-mRNA splicing, mRNA translation and stability, and post-translational assembly and stability of globin polypeptides. Only a few examples illustrating each of the major categories will be included here.",
"   </p>",
"   <p>",
"    Alpha and beta thalassemias will be considered together, because the genetic and molecular mechanisms are quite similar. The distinct features of these syndromes arise from the subsequent behaviors and amounts of the particular unpaired chains accumulating in each instance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GENE DELETIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletion of one or more alpha globin genes is the most common mechanism accounting for alpha thalassemia in Asian and Mediterranean populations. On the other hand, complete deletion of the beta globin gene has only been reported rarely, as part of larger gene rearrangement lesions. Partial beta globin gene deletions and interstitial deletions have been shown to account for rare cases of beta thalassemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Large deletions within the gene clusters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"classical\" clinically harmless pancellular forms of Hereditary Persistence of Fetal Hb (HPFH) appear to arise from deletional events that remove large regions of DNA from the beta gene cluster. In these cases, 50 to 100 kilobase long segments of DNA are deleted from downstream regions of the beta globin gene cluster. These deletions eliminate the delta and beta globin structural genes.",
"   </p>",
"   <p>",
"    Persistence of very high levels of fetal hemoglobin synthesis in adult life appears to occur in those cases in which the gene deletion brings a highly active enhancer element into close apposition with the remaining gamma globin gene(s). This enhancer, usually insulated from the globin gene cluster, provides for high levels of gamma globin gene expression and persistence of Hb F into adult life.",
"   </p>",
"   <p>",
"    Other deletions involving this region cause mild-to-moderate forms of thalassemia in which both delta and beta globin synthesis are absent (delta-beta thalassemia). The clinical prototype seems to depend on the size and location of the downstream deletions; each brings new DNA, with varying enhancer effects, in close apposition to the remaining gamma genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Deletions of the LCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very rare, but extremely informative forms of both beta and alpha thalassemia have been shown to arise from gene deletion events that remove the locus control region (LCR) sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/23\">",
"     23",
"    </a>",
"    ]. The prototypical mutation, reported in a Dutch family, was associated with total absence of beta globin synthesis, even though the beta globin gene and its surrounding promoters and enhancers were normal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chromosome responsible for this form of thalassemia was found to have undergone a large deletion many thousand bases upstream of the structural genes, through which the critical LCR sequences were lost (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ). Discovery of this family was a major finding that helped to substantiate the critical role played by the LCR in permitting expression of the globin genes during erythropoiesis. A few additional families have been found to inherit thalassemia by a similar mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GENE REARRANGEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene rearrangement events produce several distinctive and informative, forms of thalassemia (",
"    <a class=\"graphic graphic_figure graphicRef57684 \" href=\"UTD.htm?8/1/8222\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hb Lepore",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hb Lepore syndrome arises from an unequal crossing over and recombination event between the adjacent, very closely linked (5400 bases apart), and highly homologous delta and beta globin genes (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ). These events fuse the 5' end of the delta globin gene (coding for amino terminus of the delta globin chain) with the 3' end of the beta globin gene (coding for the carboxy terminal region of beta globin). The result is production of a fused (delta-beta) globin polypeptide, containing delta globin amino acids in its amino terminal portion and beta globin amino acids in its carboxy terminal portion (",
"    <a class=\"graphic graphic_figure graphicRef57684 \" href=\"UTD.htm?8/1/8222\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The fused globin (delta-beta) appears to form a functional and stable hemoglobin",
"    <span class=\"nowrap\">",
"     (alpha(2)/[delta-beta](2))",
"    </span>",
"    with altered electrophoretic mobility, called Hb Lepore. Because the production of the abnormal delta-beta globin is under the control of the delta globin promoter, which is only 2 to 3 percent as active as the beta globin promoter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/26\">",
"     26",
"    </a>",
"    ], there is severe underproduction of this abnormal globin chain (only 3 to 15 percent of normal). The chromosomal rearrangement eliminates any intact beta or delta locus from the chromosome, such that the recombination event precludes production of any normal beta globin from that chromosome. Unbalanced production of alpha and beta-like globin results, producing thalassemia of moderate-to-high severity in homozygotes. This form of thalassemia is one of the unusual forms associated with generation of a structurally abnormal hemoglobin variant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hb anti-Lepore",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb anti-Lepore results from the reciprocal chromosome product of these unequal crossover events. The anti-Lepore chromosome acquires a fused (beta-delta) chain, in which the amino terminal region is encoded by beta globin gene sequences and the carboxy terminal by delta globin gene sequences. This hemoglobin is produced at much higher levels, since it is under the control of the beta globin promoter. This chromosome also retains a normal beta and delta globin locus so that no thalassemia results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hb Kenya",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb Kenya is an interesting, clinically innocent hemoglobinopathy that results from an unequal crossover and recombination event between the beta and A(gamma) globin genes (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/27\">",
"     27",
"    </a>",
"    ]. This crossover produces a fused (A(gamma)-beta) gene. It also eliminates from the recombined chromosome all of the non-coding DNA between the A(gamma) and beta genes, as well as the delta globin gene. The only globin that can be encoded by this chromosome is thus fetal Hb containing only the G(gamma) form, and Hb Kenya containing the fused (A(gamma)-beta) chain (",
"    <a class=\"graphic graphic_figure graphicRef57684 \" href=\"UTD.htm?8/1/8222\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This event is associated with biochemical and clinical features of hereditary persistence of fetal Hb (HPFH) with the added presence of the structural variant, Hb Kenya. The persistence of high levels of fetal hemoglobin synthesis into adult life may arise because of the elimination of stage selector elements and silencers normally located between the gamma and delta genes, and the closer apposition of a strong beta globin gene enhancer normally located at the 3' side of the beta gene to the G(gamma) and Kenya genes. Hb Kenya is rare; the anti-Kenya state has not yet been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since each of the two copies of the normal alpha globin genes codes for exactly the same amino acid sequence, it is not possible to create structural alpha globin protein variants analogous to Hb Lepore and Hb Kenya by unequal crossover and recombination. However, direct analysis of globin gene DNA sequences suggests that fairly common forms of alpha thalassemia that appear to arise from a \"deletion\" of one copy of an alpha globin gene are actually due to unequal crossover and recombination events that fuse the two alpha globin genes together into one.",
"   </p>",
"   <p>",
"    The reciprocal product, containing three alpha genes, has been found in some families. These excess alpha genes can aggravate the severity of beta thalassemia because of an even greater overproduction of alpha globin chains (",
"    <a class=\"graphic graphic_table graphicRef69490 \" href=\"UTD.htm?27/53/28507\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Beta thalassemia intermedia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MUTATIONS AFFECTING TRANSCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forms of both alpha and beta thalassemia have been found to arise from mutations that alter known promoter or enhancer sequences for the alpha or beta globin genes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/29\">",
"     29",
"    </a>",
"    ]. Some of these are point mutations that alter the efficiency of the promoter or enhancer, while others are small gene deletions or rearrangement that disrupt their spatial integrity. In the aggregate these mutations account for only a small percentage of the worldwide burden of thalassemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MUTATIONS AFFECTING PRE-mRNA SPLICING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many mutations have been described that disrupt normal splicing of the mRNA precursor. Included among these are some of the most common forms of beta thalassemia and some of the more common varieties of \"non-deletion\" forms of alpha thalassemia. Only a few instructive examples shall be mentioned here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Alteration of canonical splice signals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some thalassemic splicing mutations directly disrupt the canonical \"splicing signals\" used to mark the beginning and end of each intron so that normal splicing can occur. These short sequences are absolutely required by the splicing apparatus. They signify the places at which excision of the intron, and ligation together of the flanking exons, should occur.",
"   </p>",
"   <p>",
"    Certain bases in these splicing signals are absolutely \"invariant\", such as the GT dinucleotide required at the 5' beginning of the intron and the AG dinucleotide required at the 3' end of the intron. The several bases to either side of these invariant nucleotides are consensus sequences within which alteration of the base will change the efficiency with which the site is used. Thus, mutations altering these nucleotides can abolish normal splicing or reduce it to a variable degree. Mutations that alter the consensus splice sites reduce production of alpha or beta globin mRNA; the pre-mRNA molecules which are not properly spliced appear to be catabolized rapidly, so that no abnormal mRNA products accumulate.",
"   </p>",
"   <p>",
"    In a few cases, pre-mRNAs that are not spliced at the proper sites are spliced elsewhere by activation of \"cryptic\" sites, resulting in the production of structurally abnormal, usually non-functioning messenger RNAs. The molecular basis for variability with which mutations reduce the efficiency of normal splicing, or generate production of detectable abnormally spliced products, remains poorly understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Activation of cryptic splicing sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another class of splicing mutations, one of which produces a very common form of thalassemia in the Mediterranean basin, includes those in which the mutation activates a \"cryptic\" splice site. These mutations are not located within the consensus sites at either end of introns. Rather, base substitution, small deletions, or small insertions of DNA, can convert a site within an exon or intron that normally bears only a slight resemblance to a splice site into one containing much stronger consensus signal.",
"   </p>",
"   <p>",
"    Depending upon the resulting \"strength\" of the signals, the splicing apparatus will utilize that site instead of normal site in a greater or lesser percentage of the pre-mRNA molecules being spliced. At least two spliced mRNA products result, accumulating in varying percentages, depending on the efficiency with which the cryptic site is used and the stability of the abnormally spliced product.",
"   </p>",
"   <p>",
"    This mechanism is best illustrated by a form of thalassemia commonly found in Cyprus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/30\">",
"     30",
"    </a>",
"    ]. A base substitution converts a cryptic site within the first intron of the beta globin gene into a site that is recognized as a \"strong\" splice site by the processing apparatus. Ninety percent of the pre-mRNA molecules transcribed from the mutated gene are spliced abnormally at the activated cryptic site, instead of the normal site. The mRNA product that results retains a small region (17 bases) of intron. These bases alter the reading frame or register for translation, resulting in premature translation termination. The mRNA product is useless for production of beta globin, even though it is sufficiently stable to be detected in the steady state messenger RNA of reticulocytes. Beta globin can be produced only from the small fraction (10 percent) of the mRNA molecules that are spliced at the normal position. Severe thalassemia results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hb E: A special case",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbE is the prototype of several rare forms of thalassemia in which abnormal splicing results both in reduced accumulation of translatable mRNA and the production of a structurally abnormal globin polypeptide. Formation of HbE is due to a single base substitution that alters the coding property of codon 26 in the beta globin gene. As a result, lysine is inserted as the 26th amino acid instead of the normal glutamic acid. This globin forms an",
"    <span class=\"nowrap\">",
"     (a(2)/beta(2)E)",
"    </span>",
"    hemoglobin with an altered mobility, called HbE.",
"   </p>",
"   <p>",
"    In some regions of Laos, Cambodia, Vietnam, and southern China, HbE is present in 15 to 30 percent of the population. Although HbE exhibits some measurable abnormalities in thermal stability and other properties, it appears to function quite well physiologically when inherited in a simple heterozygous (HbE trait) or homozygous state, (HbE syndrome). These patients have mild-to-moderate shortening of red cell life span and mild symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link&amp;anchor=H10#H10\">",
"     \"Introduction to hemoglobin mutations\", section on 'Hemoglobin E'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an individual who inherits HbE from one parent and beta thalassemia from the other (HbE-beta thalassemia) suffers from thalassemia intermedia or, occasionally, thalassemia major (",
"    <a class=\"graphic graphic_table graphicRef69490 \" href=\"UTD.htm?27/53/28507\">",
"     table 1",
"    </a>",
"    ). The fact that HbE interacts with beta thalassemia trait to produce a more severe form of thalassemia was puzzling until the molecular basis for this disorder was deciphered.",
"   </p>",
"   <p>",
"    The severity of HbE-beta thalassemia flows from the multiple consequences of the single base change in codon 26. This base substitution activates a cryptic splice site that is sufficiently strong that about 65 percent of the pre-mRNA is spliced at that site. The abnormally spliced mRNA is not translatable, highly unstable, and does not accumulate in the cells. The remaining 35 to 40 percent of the pre-mRNA molecules are spliced at the normal site, producing a functional, translatable, and normally stable mRNA. However, it bears the base substitution at codon 26, resulting in translation of the structural protein variant, beta(E) globin, but at only 30 to 40 percent of the normal rate. The gene is thus mildly thalassemic because a stable beta globin is produced at a reduced rate.",
"   </p>",
"   <p>",
"    This mechanism explains the long-standing observations that HbE trait presents clinically as a mild form of beta thalassemia trait, HbE homozygotes behave like patients with more marked, but benign thalassemia trait, while patients inheriting a combination of HbE and beta thalassemia suffer from a severe disease. It may also explain why HbE is such a common variant. It is a thalassemic allele in the malaria-rich regions of the world, where other thalassemia alleles are also highly prevalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link&amp;anchor=H19#H19\">",
"     \"Protection against malaria in the hemoglobinopathies\", section on 'Thalassemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other forms of both alpha and beta thalassemia have now been shown to result from molecular mechanisms analogous to that described for HbE. In most of these cases (eg, Hb Knossos [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/31\">",
"     31",
"    </a>",
"    ]), a structurally abnormal Hb variant is produced in reduced amounts because the majority of the pre-mRNA molecules are misspliced at an activated cryptic splice site created by the same base change encoding the altered amino acid in the structural variant. In a few cases, the globin produced has a normal amino acid sequence because the base substitution is translationally silent. A base substitution in codon 24 that does not alter amino acid coding but does activate a cryptic splice site results in a common, mild form of thalassemia in Africans [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ALTERED mRNA TRANSLATION AND STABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations that create a premature translation termination codon (nonsense codon) account for the most common forms of thalassemia, in terms of numbers of patients affected. These mutations create translation stop signals prematurely, so that the complete beta globin polypeptide is never made (",
"    <a class=\"graphic graphic_figure graphicRef73084 \" href=\"UTD.htm?21/53/22365\">",
"     figure 3",
"    </a>",
"    ). Rather, a truncated fragment of globin is produced. In the most common forms of thalassemia due to this mechanism, these globin fragments are highly unstable, resulting in the accumulation of no detectable protein from the mutated gene locus (ie, beta(0) thalassemia). As a result, patients homozygous for this defect cannot make any beta chains and suffer from a severe form of beta thalassemia.",
"   </p>",
"   <p>",
"    Premature translation termination can occur by base substitution or from short insertions or deletions of DNA in an exon, producing so called \"frame shift\" mutations. Unless the inserted or deleted stretch of DNA contains a number of bases that is an exact multiple of three, so that the \"open\" translation reading frame is maintained, the insertion or deletion will cause the ribosome to begin reading the codons out of register (ie, out of the normal reading frame). One consequence of this \"frame shift\" mechanism is that the probability that a UAA, UAG, or UGA translation termination codon will be encountered in register with the shifted reading frame within 50 or so bases downstream is almost 100 percent.",
"   </p>",
"   <p>",
"    In the normal reading frame, these three bases (UAA, UAG, UGA) are usually divided among two codons, and thus never \"read\" as a stop codon by the ribosome. In the shifted reading frame, the three bases will appear as a single codon and tell the ribosome to cease translation. Frame shifting is thus an alternative molecular pathway to premature translation termination. It accounts for a number of both alpha and beta thalassemia mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nonsense-mediated decay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic consequences of translation termination are very clear; no functioning globin is produced and thalassemia results. Less obvious is the phenomenon that these prematurely terminated mRNAs accumulate in greatly reduced amounts. It is not obvious why accumulation should be impaired, since their transcription, processing, and stability elements are intact. A great deal of work has shown that there are normal cell defense mechanisms to eliminate abnormally translated mRNAs. They probably exist in order to guard against the accumulation of truncated protein products, which have the potential to interact abnormally with other proteins and damage cells. This protective phenomenon is called nonsense-mediated decay and was first described for the globin genes.",
"   </p>",
"   <p>",
"    Curiously, premature stop codons that occur in the final exon of either the alpha or beta globin gene accumulate at nearly normal levels. Moreover, the truncated polypeptides also accumulate stably and in significant amounts. It appears that the process of nonsense-mediated decay affects only those mRNAs in which the premature stop codon occurs in the first or second exons. This has been found in other gene systems as well. Indeed, there is increasing evidence that nonsense-mediated decay and mRNA splicing are interactive processes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Dominant thalassemia trait due to nonsense codons in the final exon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of the failure of nonsense-mediated decay to reduce the accumulation of mRNAs carrying nonsense codons in the final exon are illustrated by the instructive phenotype associated with these mutations. In a few families with either alpha or beta thalassemia, patients with clinical manifestations of thalassemia intermedia are in fact \"simple\" heterozygotes inheriting only one allele for beta or alpha thalassemia. In another words, they inherit a dominant form of thalassemia.",
"   </p>",
"   <p>",
"    In every case studied, this dominance (ie, increased clinical severity of the heterozygous state) appears to be due to the fact that premature translation termination in the third exon results in the production of a truncated globin polypeptide that is sufficiently stable to form hemoglobin tetramers which are highly unstable. The tetramers precipitate, forming inclusion bodies and all of the downstream derangements associated with thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The globin peptides that prematurely terminate in the third exon thus behave as dominant negative mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FAILED TRANSLATION TERMINATION: Hb CONSTANT SPRING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb Constant Spring is a prototype of several mutations, some relatively common, in which altered translation and mRNA stability interact to produce severe thalassemia. Hb Constant Spring results from a single base substitution that converts the normal UAA translation termination codon in the alpha globin mRNA into a \"sense\" codon coding for an amino acid. As a result, the ribosome \"reads through\" the normal termination site and adds another 31 amino acids before it encounters an in frame stop codon in the normally 3' untranslated region.",
"   </p>",
"   <p>",
"    The elongated alpha globin polypeptide (alpha(CS)) that results from this abnormal translation event is functional and relatively stable, although it becomes modestly foreshortened by proteolysis during the life span of the red cell. However, very little (alpha(CS)) globin is produced, usually only 1 to 5 percent of the normal output from the alpha globin gene. This thalassemic behavior occurs because the amount of (alpha(CS)) mRNA is dramatically reduced, due to its marked instability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequence elements in the 3' untranslated region (3' UTR) of normal alpha globin mRNA are critical for its extraordinary stability. These elements are situated within the region that is \"read through\" in (alpha(CS)) mRNA by the ribosome as a result of the loss of the termination codon. This read through phenomenon disrupts the ability of stability elements to interact with their cognate binding proteins, resulting in the destabilization of the alpha(CS) globin mRNA (",
"    <a class=\"graphic graphic_figure graphicRef66545 \" href=\"UTD.htm?10/51/11056\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hb Constant Spring is a very common form of the alpha thalassemia in Asia. Several analogous mutations have been described. Each represents a different point mutation in the termination codon that results in a different amino acid being incorporated where termination should normally stop. In each of these cases, read through proceeds to the exact same stop signal in the 3' UTR, so that mRNA stability is affected exactly as it is for Hb Constant Spring. Other rare mutations disrupt translation termination by frame shifting. In these cases, the severity of the mRNA stability defect varies, probably depending on the point at which a new in frame termination codon is encountered, and the way in which the variable lengths of ribosomal \"read through\" interferes with the function of the 3' UTR stability elements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     POST TRANSLATIONAL MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few, relatively uncommon, mutations have been found that cause thalassemia by disrupting the structure of the fully translated globin product. These appear to interfere with normal folding of the globin peptide to form stable dimers or tetramers. In each case, the abnormal globin generates inclusion bodies and produces a thalassemia phenotype. Examples are Hb Indianapolis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9129/abstract/37\">",
"     37",
"    </a>",
"    ], which produces beta thalassemia intermedia, and Hb Quong Sze, which produces alpha thalassemia. The final common pathway for these mutations is similar to that of the dominant form of thalassemia due to nonsense codons in the final exon (see above). In both cases, substantial amounts of the abnormal protein accumulate, generating inclusion bodies by virtue of their abnormal interaction with other globin chains or heme.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalassemias arise from well over 100 mutations that, in the aggregate, affect every step required for successful production of the large amounts of Hb needed for normal red cell homeostasis. The mutations accounting for most of the thalassemia patients around the world are those affecting translation termination and mRNA splicing. Gene deletions and rearrangements, and defects affecting transcription, mRNA stability, or Hb assembly are uncommon.",
"   </p>",
"   <p>",
"    However, this later group of mutations has been highly informative, because their study has uncovered mechanisms that are highly relevant to the pathophysiology of a number of congenital and acquired disorders. Study of thalassemia, because of the extraordinarily well-characterized structure, function, and pathology of the globin gene complexes, continues to serve as a paradigm for the study of molecular medicine in general.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Steinberg MH, Benz EJ Jr. Pathobiology of the human erythrocyte and its hemoglobins. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ, Shattil SJ, et al (Eds), Churchill Livingstone, Philadelphia 2000. p.356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/2\">",
"      Horak CE, Mahajan MC, Luscombe NM, et al. GATA-1 binding sites mapped in the beta-globin locus by using mammalian chIp-chip analysis. Proc Natl Acad Sci U S A 2002; 99:2924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/3\">",
"      Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/4\">",
"      Balduini CL, Pecci A, Loffredo G, et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost 2004; 91:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/5\">",
"      Wada T, Kubota T, Fukushima Y, Saitoh S. Molecular genetic study of japanese patients with X-linked alpha-thalassemia/mental retardation syndrome (ATR-X). Am J Med Genet 2000; 94:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/6\">",
"      Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004; 103:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/7\">",
"      Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005; 105:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/8\">",
"      Haas PS, Roy NB, Gibbons RJ, et al. The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS). Br J Haematol 2009; 144:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/9\">",
"      Bank A. Understanding globin regulation in beta-thalassemia: it's as simple as alpha, beta, gamma, delta. J Clin Invest 2005; 115:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/10\">",
"      Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 2007; 109:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/11\">",
"      Weiss MJ, dos Santos CO. Chaperoning erythropoiesis. Blood 2009; 113:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/12\">",
"      dos Santos CO, Duarte AS, Saad ST, Costa FF. Expression of alpha-hemoglobin stabilizing protein gene during human erythropoiesis. Exp Hematol 2004; 32:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/13\">",
"      Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest 2004; 114:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/14\">",
"      Feng L, Zhou S, Gu L, et al. Structure of oxidized alpha-haemoglobin bound to AHSP reveals a protective mechanism for haem. Nature 2005; 435:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/15\">",
"      Yu X, Kong Y, Dore LC, et al. An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis. J Clin Invest 2007; 117:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/16\">",
"      Yu X, Mollan TL, Butler A, et al. Analysis of human alpha globin gene mutations that impair binding to the alpha hemoglobin stabilizing protein. Blood 2009; 113:5961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/17\">",
"      Baudin-Creuza V, Vasseur-Godbillon C, Pato C, et al. Transfer of human alpha- to beta-hemoglobin via its chaperone protein: evidence for a new state. J Biol Chem 2004; 279:36530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/18\">",
"      Lai MI, Jiang J, Silver N, et al. Alpha-haemoglobin stabilising protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia. Br J Haematol 2006; 133:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/19\">",
"      dos Santos CO, Zhou S, Secolin R, et al. Population analysis of the alpha hemoglobin stabilizing protein (AHSP) gene identifies sequence variants that alter expression and function. Am J Hematol 2008; 83:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/20\">",
"      Han AP, Fleming MD, Chen JJ. Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia. J Clin Invest 2005; 115:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/21\">",
"      Khandros E, Thom CS, D'Souza J, Weiss MJ. Integrated protein quality-control pathways regulate free &alpha;-globin in murine &beta;-thalassemia. Blood 2012; 119:5265.",
"     </a>",
"    </li>",
"    <li>",
"     Weatherall DJ, Clegg JB, Higgs DR, Wood WG. The hemoglobinopathies. In: The Metabolic and Molecular Bases of Inherited Disease, 7th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 1995. p.3417.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/23\">",
"      Driscoll MC, Dobkin CS, Alter BP. Gamma delta beta-thalassemia due to a de novo mutation deleting the 5' beta-globin gene activation-region hypersensitive sites. Proc Natl Acad Sci U S A 1989; 86:7470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/24\">",
"      Giordano PC, Harteveld CL, Haak HL, et al. A case of non-beta-globin gene linked beta thalassaemia in a Dutch family with two additional alpha-gene defects: the common -alpha3.7 deletion and the rare IVS1-116 (A--&gt;G) acceptor splice site mutation. Br J Haematol 1998; 103:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/25\">",
"      Viprakasit V, Kidd AM, Ayyub H, et al. De novo deletion within the telomeric region flanking the human alpha globin locus as a cause of alpha thalassaemia. Br J Haematol 2003; 120:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/26\">",
"      Humphries RK, Ley T, Turner P, et al. Differences in human alpha-, beta- and delta-globin gene expression in monkey kidney cells. Cell 1982; 30:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/27\">",
"      Ojwang PJ, Nakatsuji T, Gardiner MB, et al. Gene deletion as the molecular basis for the Kenya-G gamma-HPFH condition. Hemoglobin 1983; 7:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/28\">",
"      Kulozik AE, Thein SL, Wainscoat JS, et al. Thalassaemia intermedia: interaction of the triple alpha-globin gene arrangement and heterozygous beta-thalassaemia. Br J Haematol 1987; 66:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/29\">",
"      Sgourou A, Routledge S, Antoniou M, et al. Thalassaemia mutations within the 5'UTR of the human beta-globin gene disrupt transcription. Br J Haematol 2004; 124:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/30\">",
"      Spritz RA, Jagadeeswaran P, Choudary PV, et al. Base substitution in an intervening sequence of a beta+-thalassemic human globin gene. Proc Natl Acad Sci U S A 1981; 78:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/31\">",
"      Orkin SH, Antonarakis SE, Loukopoulos D. Abnormal processing of beta Knossos RNA. Blood 1984; 64:311.",
"     </a>",
"    </li>",
"    <li>",
"     Orkin SH, Nathan DG. The Thalassemias. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.842.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/33\">",
"      Schell T, Kulozik AE, Hentze MW. Integration of splicing, transport and translation to achieve mRNA quality control by the nonsense-mediated decay pathway. Genome Biol 2002; 3:REVIEWS1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/34\">",
"      Thein SL. Dominant beta thalassaemia: molecular basis and pathophysiology. Br J Haematol 1992; 80:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/35\">",
"      Kazazian HH Jr, Dowling CE, Hurwitz RL, et al. Dominant thalassemia-like phenotypes associated with mutations in exon 3 of the beta-globin gene. Blood 1992; 79:3014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/36\">",
"      Hunt DM, Higgs DR, Winichagoon P, et al. Haemoglobin Constant Spring has an unstable alpha chain messenger RNA. Br J Haematol 1982; 51:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9129/abstract/37\">",
"      Adams JG 3rd, Boxer LA, Baehner RL, et al. Hemoglobin Indianapolis (beta 112[G14] arginine). An unstable beta-chain variant producing the phenotype of severe beta-thalassemia. J Clin Invest 1979; 63:931.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7131 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-12B1265D54-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9129=[""].join("\n");
var outline_f8_58_9129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107740994\">",
"      CLINICAL RELEVANCE OF THE MOLECULAR BASIS OF THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOBIN GENE ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Non-globin locus mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - GATA-1 mutations and beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - ATRX mutations and alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transcription into messenger RNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - mRNA stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Translation into globin protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hemoglobin assembly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MOLECULAR LESIONS CAUSING THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GENE DELETIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Large deletions within the gene clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Deletions of the LCR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GENE REARRANGEMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hb Lepore",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hb anti-Lepore",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hb Kenya",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MUTATIONS AFFECTING TRANSCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MUTATIONS AFFECTING PRE-mRNA SPLICING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Alteration of canonical splice signals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Activation of cryptic splicing sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hb E: A special case",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ALTERED mRNA TRANSLATION AND STABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nonsense-mediated decay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Dominant thalassemia trait due to nonsense codons in the final exon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FAILED TRANSLATION TERMINATION: Hb CONSTANT SPRING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      POST TRANSLATIONAL MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7131\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7131|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/32/6656\" title=\"figure 1\">",
"      Alpha and beta globin gene clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/1/8222\" title=\"figure 2\">",
"      Lepore and Kenya hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/53/22365\" title=\"figure 3\">",
"      Genesis beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/51/11056\" title=\"figure 4\">",
"      Hb Constant Spring and mRNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7131|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/53/28507\" title=\"table 1\">",
"      Beta thal intermedia variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_58_9130="Relapsing disease in granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis";
var content_f8_58_9130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9130/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9130/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9130/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9130/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9130/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9130/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/58/9130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/58/9130/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/58/9130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15771101\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener&rsquo;s will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), have similar features on renal histology (eg, a focal necrotizing, pauci-immune glomerulonephritis), and have similar outcomes. There are, however, several differences between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 85 to 90 percent of patients with GPA or MPA attain clinical remission with initial immunosuppressive therapy (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids). They are then treated with maintenance immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , usually for a period of 12 to 18 months. However, relapses are common and some patients have frequent relapses. In addition, among patients who progress to end-stage renal disease, nonrenal relapses can occur in patients treated with maintenance hemodialysis or renal transplantation, and renal manifestations can recur in the transplanted kidney.",
"   </p>",
"   <p>",
"    Issues related to relapsing disease in patients with GPA or MPA will be reviewed here. This includes patients who have progressed to end-stage renal disease and are on chronic renal replacement therapy.",
"   </p>",
"   <p>",
"    Initial immunosuppressive therapy, the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistant disease, maintenance immunosuppressive therapy, clinical manifestations and diagnosis, and patient and renal outcomes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse is defined as the recurrence of signs or symptoms of active vasculitis in any organ system [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Relapse can be manifested by one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An active urine sediment (dysmorphic [glomerular] hematuria with or without red cell casts), which may be accompanied by a rise in serum creatinine.",
"     </li>",
"     <li>",
"      Hemoptysis or pulmonary hemorrhage or new or expanding pulmonary nodules in the absence of evidence of infection",
"     </li>",
"     <li>",
"      Iritis or uveitis, mononeuritis multiplex, sinusitis, or necrotizing vasculitis on biopsy of any tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses (also called flares) are common in patients with ANCA-associated vasculitis who attain remission. The reported rates of relapse vary widely among studies, ranging from 11 to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. In a community-based cohort in which 258 patients attained remission, 109 (42 percent) relapsed. Relapse occurred while on maintenance immunosuppressive therapy in 42 percent and after maintenance therapy had been discontinued in 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most relapses occur within the first 12 to 18 months after the cessation of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4,5,10,11\">",
"     4,5,10,11",
"    </a>",
"    ] and may or may not affect the same organ as the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. For patients who are followed closely, the majority of relapses are discovered early and are limited in nature. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Monitoring for relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The wide range of reported relapse rates is related in part to differences in therapy and the duration of follow-up. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Wegener's Granulomatosis",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      Trial (WGET trial), 90 percent of patients achieved remission at some point during active treatment but only 49 percent maintained remission during the two years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/6,12\">",
"       6,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CYCAZAREM trial in which all patients were initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      to induce remission, the relapse rate was approximately 15 percent at 18 months despite maintenance therapy with either oral cyclophosphamide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rate and time to remission'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors may have contributed to the higher rate of relapse in WGET [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relapse in WGET required only one minor manifestation compared to three minor manifestations in CYCAZAREM.",
"     </li>",
"     <li>",
"      MPA, which is less likely to relapse than GPA, was present in 39 percent of patients in CYCAZAREM compared to none in WGET.",
"     </li>",
"     <li>",
"      Not all patients received induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in WGET, as those with limited disease were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The duration of follow-up was longer in WGET (27 versus 18 months in CYCAZAREM).",
"     </li>",
"     <li>",
"      Patients continued to receive 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      in CYCAZAREM. In contrast, glucocorticoid therapy was terminated after six months in WGET if the patients were in clinical remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections have been hypothesized to trigger some disease flares by inducing expression of the ANCA antigens (PR3 and MPO) on the surface of circulating neutrophils. This can, in the presence of ANCA, lead to neutrophil degranulation, the release of oxygen radicals, and vascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for relapse were evaluated in a community-based cohort study of 350 patients with newly diagnosed ANCA-associated vasculitis who were followed for a median of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4\">",
"     4",
"    </a>",
"    ]. The following factors were associated with relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seropositivity for proteinase-3 (PR3)-ANCA, which is primarily found in GPA",
"     </li>",
"     <li>",
"      Involvement of the lung",
"     </li>",
"     <li>",
"      Involvement of the upper respiratory tract",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of relapse was much higher in patients with all three of these risk factors compared to those with none (73 percent at a median of 17 months versus 26 percent at a median of 62 months; the median time to relapse was 15 and 20 months, respectively). Among 143 patients who attained remission and were not treated with further immunosuppressive therapy, the duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    induction (&le;6 versus &gt;6 months) was NOT a risk factor for relapse (34 versus 35 percent), even in patients at high risk (41 versus 40 percent).",
"   </p>",
"   <p>",
"    Relapses are more common in patients with GPA, occurring in 25 to 80 percent of patients, than in those with MPA in whom relapse has been reported in 8 percent at 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/13\">",
"     13",
"    </a>",
"    ] and 30 to 35 percent at 7.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/15\">",
"     15",
"    </a>",
"    ]. In a series of 258 patients who attained remission, patients with PR3-ANCA, which is seen in most patients with GPA, were 1.9 times more likely to relapse than those with myeloperoxidase (MPO)-ANCA, which is seen in most patients with MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Why relapses are more common in GPA is not well understood. Proposed mechanisms include persistent granulomata [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/14\">",
"     14",
"    </a>",
"    ] and persistent PR3 expression on the membrane of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of other factors that, in different studies, have been associated with an increased risk for but do not predict relapse. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior flares, which are associated with a much greater risk of subsequent flare compared to patients who have never flared. Such patients are often treated with more prolonged maintenance therapy.",
"     </li>",
"     <li>",
"      Rapid tapering or discontinuation of glucocorticoids. In three large randomized trials in ANCA-associated vasculitis, the risk of disease flare was lowest in the CYCAZAREM trial [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/13\">",
"       13",
"      </a>",
"      ], which had the longest duration of glucocorticoid treatment (up to 18 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/6,17,18\">",
"       6,17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who remain ANCA positive during a period of clinical remission, who become ANCA positive after a period of ANCA negativity, or who have rising ANCA titers [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/10,11,19,20\">",
"       10,11,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic nasal carriage of Staphylococcus aureus [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/19,21\">",
"       19,21",
"      </a>",
"      ], which may involve the staphylococcal toxic shock syndrome toxin-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/22\">",
"       22",
"      </a>",
"      ]. The relapses were not related to diagnosed infections [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/19\">",
"       19",
"      </a>",
"      ]. The mechanisms by which S. aureus might act are not understood [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most relapses occur within the first year after the cessation of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ] and may or may not affect the same organ as the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean time to relapse is about eight to nine months, but some patients relapse early, and some relapse years after remission has been induced.",
"   </p>",
"   <p>",
"    Although the typical pattern of disease flares is involvement of the same organs affected at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/9\">",
"     9",
"    </a>",
"    ], an essential step in the evaluation of the patient with an apparent relapse is to confirm that the recurrent symptoms or signs are due to active granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA. In some cases, this decision can be made clinically if the patient has systemic symptoms and the same organ involvement as the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/13\">",
"     13",
"    </a>",
"    ]. In other patients, tissue biopsy is required to verify recurrent vasculitis rather than other factors such as infection.",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , glucocorticoids, and other therapies for ANCA-associated vasculitis remain immunosuppressed for significant periods following the cessation of these medications. Opportunistic infections are particularly important to exclude in patients with respiratory tract disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late progression of kidney disease, as defined by a rise in serum creatinine, is common. However, such progression does not necessarily imply active renal vasculitis, since two nonimmunologic mechanisms may be important in the absence of active disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular ischemia and subsequent glomerulosclerosis resulting from progressive narrowing of the vascular lumens during the healing phase of the vasculitis.",
"     </li>",
"     <li>",
"      Secondary hemodynamic and metabolic factors induced by nephron loss, such as intraglomerular hypertension in the remaining functioning glomeruli. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"       \"Secondary factors and progression of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with nonimmunologic progression have slowly progressive disease characterized by gradual increases in serum creatinine concentration and proteinuria, which is usually subnephrotic but can reach the nephrotic range without an active urinary sediment (eg, red cells and cellular casts) or other signs of disease activity. Both hypoalbuminemia and edema are unusual, even when protein excretion exceeds 3 to 4",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    An additional problem is that some renal \"relapses\" are not due to reactivation of GPA. In one report, 4 of 20 patients in remission developed new hematuria without systemic symptoms or a new elevation in serum ANCA titers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/23\">",
"     23",
"    </a>",
"    ]. Renal biopsy revealed IgA nephropathy. Repeated upper respiratory infections were common (perhaps due to continued immunosuppressive therapy) and may have promoted the development of glomerular IgA deposition. Prognosis and possible therapy in this setting are uncertain. In two of the cases, there was a lessening of hematuria following cessation of immunosuppressive therapy, suggesting that the recurrent infections may have been etiologically important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MONITORING FOR RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of modalities have been used to monitor patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA) for relapse. The most commonly used are monitoring of clinical status by the patient and physician and monitoring serum ANCA titers. The goal is maintenance of complete remission, which is defined as a",
"    <span class=\"nowrap\">",
"     BVAS/GPA",
"    </span>",
"    score of zero. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Definition of complete remission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are followed closely, the majority of relapses are discovered early and are limited in nature. Assuming the patient remains asymptomatic and urine dipstick monitoring does not reveal hematuria, we see the patient at two month intervals in the first year after remission has been induced and then every three to four months thereafter. During each visit, we make certain that the",
"    <span class=\"nowrap\">",
"     BVAS/GPA",
"    </span>",
"    score is still zero, including testing for blood in the urine and measurement of serum ANCA titers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring by the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early detection of relapse before severe tissue injury has occurred is an important component of monitoring, since reinduction of remission can usually be attained more quickly. Patient education about the manifestations of relapse and the use of urine dipsticks (for hematuria) are important components of this approach.",
"   </p>",
"   <p>",
"    We suggest that patients with renal involvement in remission urinate onto a dipstick weekly. If there is recurrent hematuria, the urine is tested again in four to seven days (since transient hematuria can occur from other causes) and, if the dipstick is still positive for blood, the patient is evaluated without delay. For premenopausal women, testing should be performed at least a few days after the cessation of menses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential confounding issue can occur in premenopausal women who often have blood in the urine during menses due to contamination from menstrual bleeding. Short of bladder catheterization, the etiology of hematuria is best determined by repeat urinalysis after the cessation of menses. This is not a common problem in patients with GPA or MPA, since the mean age is over 50 years and most affected women are postmenopausal.",
"   </p>",
"   <p>",
"    With respect to other manifestations of active vasculitis, patients typically know when they have active lung disease (which can be confirmed by CT scan), neurologic disease, or skin disease. With respect to upper respiratory tract manifestations (eg, sinusitis, otitis media, nasal ulcers and crusting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subglottic disease), active vasculitis must be distinguished from infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ANCA titers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum ANCA titers parallel the course of the vasculitis in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/10,11,19,20,24\">",
"     10,11,19,20,24",
"    </a>",
"    ]. However, a rise in ANCA titer is not consistently predictive of a disease flare, with discordant ANCA titers and disease activity occurring in as many as 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/11,20,24-30\">",
"     11,20,24-30",
"    </a>",
"    ]. These relationships can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest prospective study, the correlation between changes in disease activity and serum PR3-ANCA levels obtained at approximately three month intervals was evaluated in 156 patients with GPA enrolled during periods of active disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/25\">",
"       25",
"      </a>",
"      ]. Changes in PR3-ANCA levels explained less than 10 percent of the variation in disease activity. Only 40 percent of patients relapsed within one year after an increase in PR3-ANCA and, among patients with active disease, reductions in PR3-ANCA were not associated with a shorter time to remission.",
"     </li>",
"     <li>",
"      In an observational study of 60 patients in remission (80 percent with negative ANCA), 23 eventually had a disease flare [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/11\">",
"       11",
"      </a>",
"      ]. A rise in serum ANCA titers preceded the relapse by a mean of eight weeks in 13 of these patients, but six patients without a clinical relapse also had a sustained rise in ANCA titers and four patients relapsed with a negative ANCA. Similar findings were noted in a series of 100 patients in which 34 of 37 patients had a rise in ANCA titers prior to relapse, but, among all patients who had an increase in anti-PR3 levels, 29 percent did not relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We monitor serum ANCA titers at monthly intervals for the first 12 to 18 months, the time in which most relapses occur. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Incidence'",
"    </a>",
"    above.) We follow patients with a rise in serum ANCA titers more closely for early signs of clinical relapse, but do NOT recommend treatment for relapse based solely upon ANCA titers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse is defined as the recurrence of signs or symptoms of active vasculitis in any organ system [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In some patients, tissue biopsy is necessary to differentiate recurrent vasculitis from infection or progression due to scarring from previously active disease. However, biopsy is not necessary if there is clear evidence of new active inflammation. As an example, biopsy is not warranted in a patient who presents with a new rise in the serum creatinine and recurrence of red blood cells and red cell casts in the urine sediment. Renal biopsy is also not indication in patients who have a slow rise in serum creatinine and persistent or slowly increasing proteinuria without hematuria, which probably reflects nonimmunologic progression of previous injury. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It may be difficult to distinguish between active disease and infection (and some patients have both) when the manifestations of possible relapse are limited to the upper respiratory tract, particularly with nasal ulcers and crusting. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Upper respiratory tract disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of relapses in patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA)includes both therapy to induce remission and, once remission is attained, maintenance therapy. A variety of issues need to be addressed. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the severity of the relapse?",
"     </li>",
"     <li>",
"      Did it occur on maintenance immunosuppressive therapy or after the cessation of such therapy?",
"     </li>",
"     <li>",
"      Is this the first relapse or has the patient had multiple relapses?",
"     </li>",
"     <li>",
"      What immunosuppressive regimen should be used to treat the relapse?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Relapse severity and timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of relapse is determined by severity and by whether or not the patient is still being treated with maintenance immunosuppressive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild, non-organ-threatening relapses (eg, recurrent dysmorphic hematuria without an increase in serum creatinine) who are still receiving maintenance therapy can initially be treated by increasing the dose of glucocorticoids and of the immunosuppressive agents used for maintenance therapy (most often",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mild, non-organ threatening relapses that occur after maintenance therapy has been discontinued can be treated with reinstitution of the prior maintenance therapy and a short course (less than one month) of glucocorticoids. Maintenance therapy should be continued for a longer period than given prior to the relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with more severe relapses have traditionally been treated with reinstitution of induction therapy (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ). However a short-term randomized study (RAVE) suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be preferred to cyclophosphamide for relapsing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H75955775\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75955775\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data and a short term randomized trial have demonstrated benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with relapsing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. A multicenter noninferiority trial (RAVE) compared rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per week for four weeks) with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) in 100 patients with relapsing GPA or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/31\">",
"     31",
"    </a>",
"    ]. Both groups received one to three pulses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1000 mg) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. The majority of patients had received cyclophosphamide for initial induction therapy or prior relapse (74 percent of the cyclophosphamide group and 82 percent of the rituximab group). The rate of remission induction at six months was significantly higher with rituximab (67 versus 42 percent). There was no difference in the number of adverse events. This trial, although limited by the short duration of follow-up, suggests that rituximab may be the optimal therapy for patients who relapse following treatment with cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9244286\">",
"    <span class=\"h2\">",
"     Repeat induction therapy with cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the RAVE study, repeat induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids was the preferred option for the treatment of relapsing disease. As noted above, the RAVE trial demonstrated a higher rate of remission with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    compared to cyclophosphamide among patients with relapsing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/36\">",
"     36",
"    </a>",
"    ]. However, because the duration of follow-up in RAVE was limited to six months compared with the extensive long-term experience with cyclophosphamide, some clinicians may prefer cyclophosphamide and glucocorticoids rather than rituximab for relapsing disease.",
"   </p>",
"   <p>",
"    One problem with repeat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    induction is that increased drug exposure can lead to toxicity, particularly in patients with frequent relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. If the patient relapses after being induced twice with cyclophosphamide, we prefer a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , or, if rituximab cannot be used,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. Rituximab is also the preferred agent in patients who had difficulty tolerating initial induction therapy with cyclophosphamide. (See",
"    <a class=\"local\" href=\"#H75955775\">",
"     'Rituximab'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link&amp;anchor=H6#H6\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H16198972#H16198972\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75955782\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of MMF was illustrated in a series of 32 patients with ANCA-positive vasculitis who had a median of four relapses; the MMF dose was 1000 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/38\">",
"     38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    was considered contraindicated for a variety of reasons including previous hemorrhagic cystitis on cyclophosphamide, treated bladder cancer, bone marrow depression, patient refusal and, in six patients, an incomplete response to or relapse during cyclophosphamide therapy.",
"   </p>",
"   <p>",
"    Complete or partial remissions were obtained in 78 and 19 percent, respectively. Relapse during follow-up occurred in 19 of 25 patients (76 percent) who attained complete remission and in all six who attained partial remission. Patients who had previously been treated successfully with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    had a better response than those who had not (complete remission 84 versus 50 percent, relapse 50 versus 100 percent). The median time to relapse and was similar to the previous median time to relapse (16 versus 17 months) and all but two patients were still taking MMF at the time to relapse. The other two patients relapsed after MMF had been discontinued (at 16 and 41 months) and were successfully treated with a second course of MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26698981\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with non-organ-threatening and non-life-threatening disease who were initially treated with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based regimen can be retreated with",
"    <strong>",
"    </strong>",
"    methotrexate if the relapse is mild and the estimated glomerular filtration rate is greater than 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Choice of cyclophosphamide regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H19#H19\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Upper respiratory tract disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to distinguish between active disease and infection (and some patients have both) when the manifestations of possible relapse are limited to the upper respiratory tract, particularly with nasal disease where ulceration and crusting over granulation tissue can result from both vasculitis and infection. Endoscopic examination by an experienced ear nose and throat physician may establish a definitive diagnosis but often show only nonspecific acute and chronic inflammation.",
"   </p>",
"   <p>",
"    The therapeutic approach varies with the presumed diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When infection is thought to be the predominant problem, oral antibiotics are often required (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ). However, some prefer topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      ointment for less severe infections. The ointment can be applied directly inside of each nostril or mixed into a saline irrigation solution. Topical antibiotics have the advantage of permitting a long course of therapy without the systemic side effects that may be seen with oral antibiotics.",
"     </li>",
"     <li>",
"      When active vasculitis is thought to be the predominant problem and the relapse is limited to the upper respiratory tract, we increase the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose for at least four weeks and continue or increase the dose of the drug used for maintenance immunosuppression.",
"     </li>",
"     <li>",
"      When infection and active vasculitis cannot be distinguished, we treat both simultaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Management of upper airway involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two questions related to maintenance after remission from the relapse has been attained: what drug should be used and what is the duration of maintenance therapy.",
"   </p>",
"   <p>",
"    The usual drugs for maintenance therapy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and, in patients with an estimated glomerular filtration rate above 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Alternative agents in patients who do not respond to or tolerate these drugs are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The supportive evidence for efficacy and dosing regimens for the different drugs are discussed elsewhere. Most patients are also treated with glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of drug and the duration of maintenance therapy are determined in part by the timing of relapse. In a community-based cohort of 109 patients who attained remission and then relapsed, relapse occurred while on maintenance immunosuppressive therapy in 42 percent and after maintenance therapy had been discontinued in 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who relapse while on maintenance therapy, a different drug should be used for maintenance therapy after reinduction of remission. In such patients, the duration of maintenance therapy may be similar to that suggested for the original course of maintenance therapy (usually 12 to 18 months but can vary with the estimated likelihood of relapse). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link&amp;anchor=H10#H10\">",
"       \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Duration of maintenance therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who relapse after the cessation of maintenance therapy, the same drug can be used for maintenance therapy after remission has been induced, but the duration should be substantially longer than the initial course. For patients who have frequent relapses, life-long maintenance therapy may be appropriate, similar to that in transplant recipients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoid therapy is part of the maintenance immunosuppression regimen. The median duration of glucocorticoid therapy after the first induction of remission is less than six to eight months. Some experts recommend long-term, low dose maintenance therapy in patients who have had multiple relapses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link&amp;anchor=H11#H11\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    is an effective maintenance drug for the prevention of relapses limited to the upper respiratory tract. However, toxicity is an issue since, in the randomized trial suggesting benefit compared to placebo in this setting, 20 percent of patients treated with trimethoprim-sulfamethoxazole maintenance discontinued therapy due to side effects, most of which are minor (anorexia, nausea, rash) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECT ON PATIENT AND RENAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of relapses on patient and renal outcomes was evaluated in the community-based cohort cited above of 350 patients with a new diagnosis of ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/4\">",
"     4",
"    </a>",
"    ]. There were two main findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comparing patients who did or did not relapse, there was no significant difference in all-cause mortality (adjusted hazard ratio 1.5, 95% CI 0.8-2.6).",
"     </li>",
"     <li>",
"      In contrast, patients who relapsed had, after adjusting for other factors including time, a significant increase in the risk of developing end-stage renal disease (28 percent at 5.5 years versus 19 percent at 9 years, adjusted likelihood of progression to end-stage renal disease 4.7). The increase in risk was entirely due to recurrent nephritis since this complication was not seen in patients with nonrenal relapses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis (MPA) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHRONIC RENAL REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA) progress to end-stage renal disease and require chronic renal replacement therapy with chronic dialysis or renal transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Maintenance dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of relapsing disease in patients on maintenance dialysis will be reviewed in this section. General issues in these patients, including long-term outcomes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link&amp;anchor=H7#H7\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Maintenance dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Rate of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses occur in patients on maintenance dialysis, but the rate has been lower than that in patients with preserved renal function in most [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/40-43\">",
"     40-43",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/44\">",
"     44",
"    </a>",
"    ]. A report from the Glomerular Disease Collaborative Network is by far the largest reported series, as data on relapse rates were available in 452 patients with ANCA-associated systemic vasculitis, 93 of whom progressed to end-stage renal disease and chronic dialysis at a median follow-up of 40 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/40\">",
"     40",
"    </a>",
"    ]. The relapse rate in the patients who had end-stage renal disease was 0.08 episodes per patient-year, which was significantly lower than the 0.2 episodes per patient-year in the same patients before dialysis was required and the 0.16 episodes per patient-year in the 359 patients who did not develop end-stage renal disease.",
"   </p>",
"   <p>",
"    The rate of relapse and the effect of dialysis were different in patients with PR3-ANCA and MPO-ANCA. The rate of relapse was high before dialysis and fell substantially after dialysis in patients with PR3-ANCA (0.34 to 0.11 episodes per person-year), while the rate was low before dialysis and did not change significantly after dialysis in patients with MPO-ANCA (0.06 and 0.04 episodes per person-year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Morbidity of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vasculitis in patients requiring chronic dialysis may be associated with significant morbidity and mortality due to at least two factors: the adverse effects of maintenance immunosuppression; and misdiagnosis of relapsing disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the above study that included 93 patients on chronic dialysis, infection was almost twice as common in patients taking maintenance immunosuppression (1.9 versus 1 episodes per person per year in patients not receiving immunosuppressive therapy) and was a more frequent cause of death that in patients with preserved renal function (43 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link&amp;anchor=H8#H8\">",
"       \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Importance of infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The potential importance of misdiagnosis was illustrated in a report of 37 patients in which three of ten relapses among seven patients were fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/42\">",
"       42",
"      </a>",
"      ]. These fatal events were initially interpreted as complications of the dialysis procedure: however, in the three deaths, vasculitis of the gastrointestinal tract was first treated as peritonitis due to peritoneal dialysis, and lung hemorrhage was misdiagnosed as pulmonary edema resulting from fluid overload.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Treatment of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and other investigators treat relapse in chronic dialysis patients with GPA or MPA the same as in those who do not require dialysis, with the duration of therapy and therapeutic regimen being based upon patient response. In one report, remission or partial remission was attained in 93 percent of relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/44\">",
"     44",
"    </a>",
"    ]. Given the increased risk of severe bone marrow suppression in this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    must be used very cautiously (if at all) with careful monitoring, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should NOT be used for either initial or maintenance therapy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dose adjustment for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in dialysis patients is not well defined. A suggested approach for oral cyclophosphamide is 50 percent of the usual dose after each hemodialysis session and 75 percent of the usual dose in patients on continuous ambulatory peritoneal dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H20#H20\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Use of daily oral cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dose adjustment may be also be warranted for other drugs that might be used for induction or maintenance therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (suggested maximum dose 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/45\">",
"     45",
"    </a>",
"    ], but apparently not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The lower rate of relapse and the higher risk of infection with immunosuppressive therapy in dialysis patients suggest that a shorter duration of maintenance therapy may be beneficial. Among patients without active disease who progress to dialysis while on maintenance therapy, we discontinue maintenance therapy in those who have been treated for at least three to six months.",
"   </p>",
"   <p>",
"    Similar considerations apply to patients who have relapsed while on maintenance dialysis in whom remission has been induced. We try to limit maintenance therapy to three to six months for the first relapse to minimize the risk of infection. The infrequent dialysis patients who have multiple relapses that occur after cessation of maintenance therapy will require more prolonged maintenance therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of relapsing disease in patients who have undergone renal transplantation will be reviewed in this section. General issues in these patients, including long-term outcomes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link&amp;anchor=H9#H9\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transplantation should be delayed for at least six months from the time of initial presentation or most recent relapse. Persistence of isolated ANCA positivity is NOT a contraindication to renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is only a limited experience with renal transplantation in patients with GPA and MPA. Isolated reports indicate that both the renal and extrarenal manifestations can recur after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/46-53\">",
"     46-53",
"    </a>",
"    ]. The transplanted ureter also may be involved, possibly leading to ureteral stenosis and obstructive uropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Risk of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of relapse among renal transplant recipients may be lower than that in patients continued on maintenance dialysis, probably due at least in part to maintenance immunosuppressive therapy to prevent transplant rejection. In a retrospective analysis of 59 patients treated with chronic dialysis, transplantation, or both who were seen between 1974 and 1997, the rates of relapse were 0.02 and 0.09 per patient per year with transplantation and chronic dialysis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of relapse in the current era of immunosuppression is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/46-49,52\">",
"     46-49,52",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One estimate comes from a 1999 pooled analysis of published data in 127 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/46\">",
"       46",
"      </a>",
"      ]. ANCA-positive small vessel vasculitis recurred in 17 percent; the average time to relapse was 31 months. The rate of relapse was not affected by the type of vasculitis (GPA versus MPA) or the presence or absence of ANCA at the time of transplantation. Of 21 patients for whom data were available, 12 had relapses involving the kidney and 10 had relapses limited to extrarenal sites, including upper respiratory tract (8), lungs (6), gut (2), skin (4), joints (5) and eyes (2).",
"     </li>",
"     <li>",
"      Similar conclusions were reached in a 2007 report of 35 patients from the Mayo Clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/47\">",
"       47",
"      </a>",
"      ]. The most common immunosuppressive regimen consisted of antibody induction therapy, glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . Nonrenal relapse occurred in three patients at mean follow-up of 4.4 years and had a satisfactory response to therapy. There was no clear risk factor for relapse and no evidence of a detrimental effect of relapse on renal function.",
"     </li>",
"     <li>",
"      In a third report of 19 patients, seven (37 percent) had recurrent vasculitis at a mean follow-up of 45 months, all of which involved the kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?8/58/9130/abstract/48\">",
"       48",
"      </a>",
"      ]. Two patients also had pulmonary involvement and one had cutaneous vasculitis. Death-censored graft survival was 84 percent compared to 100 percent in 38 matched controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Therapy of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease flares following renal transplantation, particularly if severe, usually require the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and the discontinuation of some transplant medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26699023\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse is defined as the recurrence of signs or symptoms of active vasculitis in any organ system. Relapse can be manifested by one or more of the following features: an active urine sediment with or without a rise in serum creatinine; hemoptysis or pulmonary hemorrhage or new or expanding pulmonary nodules in the absence of evidence of infection; or iritis or uveitis, mononeuritis multiplex, sinusitis, or necrotizing vasculitis on biopsy of any tissue. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most relapses occur within the first year after the cessation of immunosuppressive therapy and may or may not affect the same organ as the initial presentation. It is essential to confirm that the recurrent symptoms or signs are due to active vasculitis and not infection or late nonimmunologic progression of kidney disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients be monitored for relapse every two months during the first year after remission and every three to four months thereafter. During each visit the patient&rsquo;s clinical status, renal function and a urine dipstick for hematuria should be checked. In addition, we suggest that patients with renal involvement who are in remission monitor for hematuria by urinating onto a dipstick weekly. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Monitoring for relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum ANCA titers may parallel the course of the vasculitis in some patients but do not consistently predict disease flare. We monitor monthly serum ANCA titers for the first 12 to 18 months. We follow patients with a rise in serum ANCA titers closely for early signs of clinical relapse, but do NOT recommend treatment for relapse based solely upon ANCA titers. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'ANCA titers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of relapse is determined by severity and by whether or not the patient is still being treated with maintenance immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with mild, non-organ-threatening relapses who are still receiving maintenance therapy can be treated by increasing the dose of glucocorticoids and of the immunosuppressive agents used for maintenance therapy (most often",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mild, non-organ threatening relapses that occur after maintenance therapy has been discontinued can be treated with reinstitution of the prior maintenance therapy and a short course (less than one month) of glucocorticoids.",
"     </li>",
"     <li>",
"      Patients with more severe relapses may be treated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Rituximab is the preferred agent for patients who relapse after being induced with cyclophosphamide, or have had difficulty tolerating initial induction therapy with cyclophosphamide. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy following relapse is determined in part by the timing of relapse. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maintenance therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who relapse while on maintenance therapy, a different drug should be used for maintenance therapy after reinduction of remission.",
"     </li>",
"     <li>",
"      For patients who relapse after the cessation of maintenance therapy, the same drug can be used for maintenance therapy after remission has been induced, but the duration should be substantially longer than the initial course.",
"     </li>",
"     <li>",
"      For patients who have frequent relapses, life-long maintenance therapy may be appropriate, similar to that in transplant recipients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic dialysis patients who relapse are treated the same as those who do not require dialysis, with the duration of therapy and therapeutic regimen being based upon patient response. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/4\">",
"      Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/5\">",
"      Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/6\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/7\">",
"      Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/8\">",
"      Reinhold-Keller E, Fink CO, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/9\">",
"      Chen M, Yu F, Zhao MH. Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. J Rheumatol 2008; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/10\">",
"      Geffriaud-Ricouard C, No&euml;l LH, Chauveau D, et al. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/11\">",
"      Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/12\">",
"      Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/13\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/14\">",
"      Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/15\">",
"      Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/16\">",
"      Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/17\">",
"      De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/18\">",
"      Goek ON, Stone JH. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol 2005; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/19\">",
"      Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/20\">",
"      Kyndt X, Reumaux D, Bridoux F, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/21\">",
"      Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med 2003; 42:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/22\">",
"      Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/23\">",
"      Andrassy K, Waldherr R, Erb A, Ritz E. De novo glomerulonephritis in patients during remission from Wegener's granulomatosis. Clin Nephrol 1992; 38:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/24\">",
"      Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/25\">",
"      Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/26\">",
"      Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/27\">",
"      Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/28\">",
"      Gaskin G, Savage CO, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/29\">",
"      Tervaert JW, Huitema MG, Hen&eacute; RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/30\">",
"      Russell KA, Fass DN, Specks U. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001; 44:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/31\">",
"      Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/32\">",
"      Aouba A, Pagnoux C, Bienvenu B, et al. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin Rev Allergy Immunol 2008; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/33\">",
"      Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/34\">",
"      Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/35\">",
"      Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 2010; 363:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/36\">",
"      Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/37\">",
"      Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999; 70:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/38\">",
"      Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/39\">",
"      Stegeman, CA, Cohen Tervaert, JW, de Jong, PE, Kallenberg, CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/40\">",
"      Lionaki S, Hogan SL, Jennette CE, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 2009; 76:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/41\">",
"      Falk RJ, Nachman PH, Hogan SL, Jennette JC. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol 2000; 20:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/42\">",
"      Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998; 9:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/43\">",
"      Weidanz F, Day CJ, Hewins P, et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 2007; 50:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/44\">",
"      Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998; 13:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/45\">",
"      Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/46\">",
"      Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999; 56:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/47\">",
"      Gera M, Griffin MD, Specks U, et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 2007; 71:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/48\">",
"      Moroni G, Torri A, Gallelli B, et al. The long-term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007; 7:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/49\">",
"      Elmedhem A, Adu D, Savage CO. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003; 18:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/50\">",
"      Steinman TI, Jaffe BF, Monaco AP, et al. Recurrence of Wegener's granulomatosis after kidney transplantation. Successful re-induction of remission with cyclophosphamide. Am J Med 1980; 68:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/51\">",
"      Clarke AE, Bitton A, Eappen R, et al. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation 1990; 50:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/52\">",
"      Rostaing L, Modesto A, Oksman F, et al. Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997; 29:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/53\">",
"      Haubitz M, Kliem V, Koch KM, et al. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 1997; 63:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/58/9130/abstract/54\">",
"      Rich LM, Piering WF. Ureteral stenosis due to recurrent Wegener's granulomatosis after kidney transplantation. J Am Soc Nephrol 1994; 4:1516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3040 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9130=[""].join("\n");
var outline_f8_58_9130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26699023\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15771101\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MONITORING FOR RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring by the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANCA titers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Relapse severity and timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75955775\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9244286\">",
"      Repeat induction therapy with cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75955782\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26698981\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Upper respiratory tract disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECT ON PATIENT AND RENAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHRONIC RENAL REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Rate of relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Morbidity of relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Treatment of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Risk of relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Therapy of relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26699023\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=related_link\">",
"      Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=related_link\">",
"      Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=related_link\">",
"      Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=related_link\">",
"      Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_58_9131="Primary AED therapy";
var content_f8_58_9131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary AED therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Initial IV dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Rate of infusion",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Lorazepam",
"      </td>",
"      <td>",
"       0.05-0.1 mg/kg",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       2 mg/min (maximum dose 4 mgm)",
"      </td>",
"      <td>",
"       Sedation, hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       May repeat in 5-10 min",
"      </td>",
"      <td>",
"       Respiratory depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Fosphenytoin",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       15-20 pheytoin equivalents/kg IV",
"      </td>",
"      <td>",
"       3 mg/kg/min",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1500 mgm PE/24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum 150 mgm/min",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    AED: antiepileptic drug",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9131=[""].join("\n");
var outline_f8_58_9131=null;
var title_f8_58_9132="Comb modal tox HL";
var content_f8_58_9132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxicities associated with combination chemotherapy and radiation therapy for Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute toxicities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alopecia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresthesias and neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS confusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia, leukopenia, and thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disulfiram-like reaction following alcohol while taking procarbazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Delayed toxicities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Secondary malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute myelogenous leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute lymphoblastic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast, gastric, lung, and thyroid cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Pulmonary complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleomycin lung toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Accelerated atherosclerotic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pericardial fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Endocrine complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infertility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9132=[""].join("\n");
var outline_f8_58_9132=null;
var title_f8_58_9133="Post CABG AF risk index";
var content_f8_58_9133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multivariable risk index for postoperative atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Predictor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk points*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        &lt;30",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        30 - 39",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        40 - 49",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        50 - 59",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        60 - 69",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        70 - 79",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        &ge;80",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Medical history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        AF",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        COPD",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Concurrent valve",
"surgery",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Withdrawal of",
"treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        Beta",
"blockers",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        ACE",
"inhibitors",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Preoperative and",
"postoperative treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        Beta",
"blockers",
"       </td>",
"       <td>",
"        - 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        ACE",
"inhibitors",
"       </td>",
"       <td>",
"        - 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Postoperative",
"beta blocker treatment",
"       </td>",
"       <td>",
"        - 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Other treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        Potassium",
"supplementation",
"       </td>",
"       <td>",
"        - 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"1\">",
"        NSAIDs",
"       </td>",
"       <td>",
"        - 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sum of risk points",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk rank",
"       </td>",
"       <td class=\"subtitle1\">",
"        Postoperative AF risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;14&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        &lt; 17 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14 - 31",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        17 to 52 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;31",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        &gt; 52 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; ACE inhibitors: angiotensin converting enzyme inhibitors; NSAIDs: nonsteroidal antiinflammatory drugs.",
"     <br>",
"      * To calculate the estimated risk of postoperative atrial fibrillation, the sum of the risk points is determined. Scores are stratified into low risk (&lt;14 points; AF incidence &lt;17 percent), medium risk (14 to 31 points; AF incidence 17 to 52 percent) and high risk (&gt;31 points; AF incidence &gt;52 percent).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Mathew JP, et al. JAMA 2004; 291:1720.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9133=[""].join("\n");
var outline_f8_58_9133=null;
var title_f8_58_9134="BCR-ABL FISH in CML";
var content_f8_58_9134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interphase fluorescence in situ hybridization (FISH) images of normal and t(9;22) positive nuclei",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dual-color ABL (green) and BCR (red) probes span their respective breakpoint regions, producing two red and two green signals in a normal nucleus (on the left). In the t(9;22) cell (on the right), the single red and green signals correspond to the normal ABL and BCR genes, respectively, while the two yellow-white fusion signals correspond to the Ph chromosome and the reciprocal balanced translocation product (derivative chromosome 9).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Athena Cherry, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9134=[""].join("\n");
var outline_f8_58_9134=null;
var title_f8_58_9135="Solute reabsorption by kidney";
var content_f8_58_9135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solute reabsorption by the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 164px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of the net daily reabsorptive work performed by the kidney. These values are for a normal adult man on a typical Western diet. The glomerular filtration rate and therefore the filtered load of solutes and water is approximately 25 percent lower in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_58_9135=[""].join("\n");
var outline_f8_58_9135=null;
